[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fKro2-BgKiB4WSWEsT1ezxj5cZ_AdhlkpB34nqpt017w":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"Centre Hospitalier Universitaire de Nice",[4],692,false,175,29,155251,48,562,[14,17,20,22,25,27,30,32],{"name":15,"count":16},"Alzheimer Disease",13,{"name":18,"count":19},"Multiple Sclerosis",12,{"name":21,"count":19},"Vitiligo",{"name":23,"count":24},"Alzheimer's Disease",8,{"name":26,"count":24},"Obesity",{"name":28,"count":29},"COVID",7,{"name":31,"count":29},"Rheumatoid Arthritis",{"name":33,"count":34},"Melanoma",6,[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04920812","MITOMICS : a Multi-OMICS Approach for the Diagnosis of Mitochondrial Diseases","2022-03-07","diagnosis of mitochondrial myopathy",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04747041","Evaluation of a Phyto Aromatherapy Treatment in the Management of Recurrent Cystitis","2023-06-20","CYSCONTROL\u002FPHYTOCYST Herbal tea",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04925414","Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)","2025-04","oxygenotherapy",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04829565","Assessment of Pain After Intra-articular Botulinum Toxin Injections in Carpometacarpal Osteoarthritis of the Thumb","2025-05-15","Botulinum toxin",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT04406259","Atrioventricular Block and Cluster Headache (SEVA)","2025-09-05","Verapamil",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06136403","A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses","2025-09-30","deucravacitinib",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06509984","A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized","2025-10-01","Apremilast treatment",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06528171","Covid-19 Long Immunité IMagerie (CLIIM)","2025-12","Specific blood samples",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT06133907","Investigation of the Frequency of Hereditary Hyper Alpha-tryptasemia in Patients With Elevated Basal Tryptasemia","2025-12-05","Serum",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06815133","Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 Months","2026-02-01","Zilbrysq",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,119,146,164,190,217,235,259,286,304,325,346,386,411,437,455,480,505,532,550,587,608,632,657,684,702,729,747,771,789,813,836,860,882,908,934,958,984,1007,1031,1055,1081,1106,1132,1153,1174,1196,1220,1241,1274,1299,1324,1342,1367,1393,1419,1437,1463,1488,1506,1532,1550,1576,1594,1619,1644,1669,1696,1714,1740,1766,1784,1808,1832,1857,1881,1903,1928,1955,1973,1996,2021,2046,2070,2093,2116,2142,2167,2193,2214,2239,2264,2282,2306,2331,2355,2380,2404,2429,2454,2478,2503,2526,2549,2576,2594,2612,2630,2661,2694,2728,2764,2790,2808,2832,2857,2882,2908,2933,2959,2983,3006,3030,3053,3077,3103,3126,3149,3173,3198,3222,3245,3269,3292,3316,3342,3365,3390,3417,3435,3461,3485,3509,3534,3559],{"intervention":55,"totalTrials":95,"cells":96},1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":117},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":54},[108],{"nctId":52,"briefTitle":53,"status":109,"phases":110,"primaryCompletion":54,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"ACTIVE_NOT_RECRUITING",[91],"2026-05-15","2021-09-09",60,[115],"Rhizarthrosis",[55],{"trials":118,"activeCount":99},[],{"intervention":120,"totalTrials":95,"cells":121},"Experimental: dose binding arm",{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":144},{"trials":123,"activeCount":99},[],{"trials":125,"activeCount":99},[],{"trials":127,"activeCount":99},[],{"trials":129,"activeCount":99},[],{"trials":131,"activeCount":95,"soonestReadout":137},[132],{"nctId":133,"briefTitle":134,"status":135,"phases":136,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":142},"NCT07582185","Tdose Binding and Tocilizumab","NOT_YET_RECRUITING",[91],"2026-09-30","2026-12-31","2026-06-01",122,[31],[120,143],"Active Comparator: traditionnal arm: Weight-based dosing",{"trials":145,"activeCount":99},[],{"intervention":143,"totalTrials":95,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":162},{"trials":149,"activeCount":99},[],{"trials":151,"activeCount":99},[],{"trials":153,"activeCount":99},[],{"trials":155,"activeCount":99},[],{"trials":157,"activeCount":95,"soonestReadout":137},[158],{"nctId":133,"briefTitle":134,"status":135,"phases":159,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":160,"interventions":161},[91],[31],[120,143],{"trials":163,"activeCount":99},[],{"intervention":165,"totalTrials":95,"cells":166},"Efgartigimod",{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":175,"NA":188},{"trials":168,"activeCount":99},[],{"trials":170,"activeCount":99},[],{"trials":172,"activeCount":99},[],{"trials":174,"activeCount":99},[],{"trials":176,"activeCount":95,"soonestReadout":182},[177],{"nctId":178,"briefTitle":179,"status":180,"phases":181,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},"NCT07072988","Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod","RECRUITING",[91],"2027-10-01","2025-09-19",50,[186],"Myasthenia Gravis, Generalized",[165],{"trials":189,"activeCount":99},[],{"intervention":191,"totalTrials":95,"cells":192},"Fluid resuscitation with isotonic saline only",{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":199,"PHASE4":201,"NA":215},{"trials":194,"activeCount":99},[],{"trials":196,"activeCount":99},[],{"trials":198,"activeCount":99},[],{"trials":200,"activeCount":99},[],{"trials":202,"activeCount":95,"soonestReadout":207},[203],{"nctId":204,"briefTitle":205,"status":180,"phases":206,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"NCT06541535","Fluid Administration in Ketoacidosis (DRINK)",[91],"2027-12","2028-07","2025-11-26",300,[212],"Diabetic Keto-acidosis",[191,214],"Fluid resuscitation with Ringer Lactate",{"trials":216,"activeCount":99},[],{"intervention":214,"totalTrials":95,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":227,"NA":233},{"trials":220,"activeCount":99},[],{"trials":222,"activeCount":99},[],{"trials":224,"activeCount":99},[],{"trials":226,"activeCount":99},[],{"trials":228,"activeCount":95,"soonestReadout":207},[229],{"nctId":204,"briefTitle":205,"status":180,"phases":230,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":231,"interventions":232},[91],[212],[191,214],{"trials":234,"activeCount":99},[],{"intervention":236,"totalTrials":95,"cells":237},"Empagliflozin 10 MG then Placebo",{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":257},{"trials":239,"activeCount":99},[],{"trials":241,"activeCount":99},[],{"trials":243,"activeCount":99},[],{"trials":245,"activeCount":99},[],{"trials":247,"activeCount":95,"soonestReadout":207},[248],{"nctId":249,"briefTitle":250,"status":135,"phases":251,"primaryCompletion":207,"completion":207,"start":252,"enrollment":253,"conditions":254,"interventions":256},"NCT07074418","Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml\u002FMin\u002F1.73m2",[91],"2026-04",34,[255],"Chronic Kidney Diseases",[236],{"trials":258,"activeCount":99},[],{"intervention":260,"totalTrials":95,"cells":261},"Administration of METHOXYFLURANE",{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":270,"NA":284},{"trials":263,"activeCount":99},[],{"trials":265,"activeCount":99},[],{"trials":267,"activeCount":99},[],{"trials":269,"activeCount":99},[],{"trials":271,"activeCount":95,"soonestReadout":276},[272],{"nctId":273,"briefTitle":274,"status":180,"phases":275,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":282},"NCT05821517","METHOXYFLURANE or Virtual Reality Headset vs Standard Analgesic Management for the Reduction of Anterior Shoulder Dislocation (HYPNOLUX)",[91],"2026-12-30","2027-03","2023-12-30",150,[281],"Anterior Shoulder Dislocation",[260,283],"Standard of care",{"trials":285,"activeCount":99},[],{"intervention":283,"totalTrials":95,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":302},{"trials":289,"activeCount":99},[],{"trials":291,"activeCount":99},[],{"trials":293,"activeCount":99},[],{"trials":295,"activeCount":99},[],{"trials":297,"activeCount":95,"soonestReadout":276},[298],{"nctId":273,"briefTitle":274,"status":180,"phases":299,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":300,"interventions":301},[91],[281],[260,283],{"trials":303,"activeCount":99},[],{"intervention":60,"totalTrials":95,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":312,"PHASE4":314,"NA":323},{"trials":307,"activeCount":99},[],{"trials":309,"activeCount":99},[],{"trials":311,"activeCount":99},[],{"trials":313,"activeCount":99},[],{"trials":315,"activeCount":95,"soonestReadout":59},[316],{"nctId":57,"briefTitle":58,"status":109,"phases":317,"primaryCompletion":59,"completion":318,"start":319,"enrollment":113,"conditions":320,"interventions":322},[91],"2027-09-05","2020-11-02",[321],"Cluster Headache",[60],{"trials":324,"activeCount":99},[],{"intervention":50,"totalTrials":95,"cells":326},{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":335,"NA":344},{"trials":328,"activeCount":99},[],{"trials":330,"activeCount":99},[],{"trials":332,"activeCount":99},[],{"trials":334,"activeCount":99},[],{"trials":336,"activeCount":95,"soonestReadout":49},[337],{"nctId":47,"briefTitle":48,"status":180,"phases":338,"primaryCompletion":49,"completion":49,"start":339,"enrollment":340,"conditions":341,"interventions":343},[91],"2023-10-01",70,[342],"Migraine",[50],{"trials":345,"activeCount":99},[],{"intervention":347,"totalTrials":348,"cells":349},"RiTUXimab",2,{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":369,"PHASE4":382,"NA":384},{"trials":351,"activeCount":99},[],{"trials":353,"activeCount":99},[],{"trials":355,"activeCount":99},[356],{"nctId":357,"briefTitle":358,"status":359,"phases":360,"primaryCompletion":361,"completion":362,"start":363,"enrollment":364,"conditions":365,"interventions":367},"NCT03804359","Personalized Medicine for Membranous Nephropathy","COMPLETED",[89],"2024-09-30","2024-11-05","2020-01-14",68,[366],"Idiopathic Membranous Nephropathy",[368],"Rituximab",{"trials":370,"activeCount":95,"soonestReadout":375},[371],{"nctId":372,"briefTitle":373,"status":180,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":381},"NCT06341205","Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)",[90],"2031-08-31","2031-09-30","2025-02-04",120,[380],"Membranous Nephropathy",[347],{"trials":383,"activeCount":99},[],{"trials":385,"activeCount":99},[],{"intervention":387,"totalTrials":95,"cells":388},"Ocrelizumab",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":407,"NA":409},{"trials":390,"activeCount":99},[],{"trials":392,"activeCount":99},[],{"trials":394,"activeCount":99},[],{"trials":396,"activeCount":95,"soonestReadout":401},[397],{"nctId":398,"briefTitle":399,"status":109,"phases":400,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":406},"NCT05210621","LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB",[90],"2026-02-24","2029-02-24","2022-03-08",72,[18],[387],{"trials":408,"activeCount":99},[],{"trials":410,"activeCount":99},[],{"intervention":412,"totalTrials":95,"cells":413},"amoxicillin or moxifloxacin",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":433,"NA":435},{"trials":415,"activeCount":99},[],{"trials":417,"activeCount":99},[],{"trials":419,"activeCount":99},[],{"trials":421,"activeCount":95,"soonestReadout":426},[422],{"nctId":423,"briefTitle":424,"status":135,"phases":425,"primaryCompletion":426,"completion":426,"start":427,"enrollment":428,"conditions":429,"interventions":431},"NCT05902221","Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections",[90],"2027-07-01","2024-03-30",235,[430],"Infections Joint Prosthetic",[412,432],"amoxicillin or moxifloxacin + rifampicin",{"trials":434,"activeCount":99},[],{"trials":436,"activeCount":99},[],{"intervention":432,"totalTrials":95,"cells":438},{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":445,"PHASE4":451,"NA":453},{"trials":440,"activeCount":99},[],{"trials":442,"activeCount":99},[],{"trials":444,"activeCount":99},[],{"trials":446,"activeCount":95,"soonestReadout":426},[447],{"nctId":423,"briefTitle":424,"status":135,"phases":448,"primaryCompletion":426,"completion":426,"start":427,"enrollment":428,"conditions":449,"interventions":450},[90],[430],[412,432],{"trials":452,"activeCount":99},[],{"trials":454,"activeCount":99},[],{"intervention":456,"totalTrials":95,"cells":457},"OXYGENE MEDICINAL LIQUIDE AIR PRODUCTS MEDICAL",{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":464,"PHASE4":476,"NA":478},{"trials":459,"activeCount":99},[],{"trials":461,"activeCount":99},[],{"trials":463,"activeCount":99},[],{"trials":465,"activeCount":95,"soonestReadout":470},[466],{"nctId":467,"briefTitle":468,"status":135,"phases":469,"primaryCompletion":470,"completion":471,"start":139,"enrollment":472,"conditions":473,"interventions":475},"NCT07557693","Mitochondrial Network Modulation Approach Using Hyperbaric Oxygen (HBO) Therapy and Nb-UVB for Treating Vitiligo",[89,90],"2027-06-01","2027-12-31",5,[474],"Vitiligo Vulgaris",[456],{"trials":477,"activeCount":99},[],{"trials":479,"activeCount":99},[],{"intervention":481,"totalTrials":95,"cells":482},"Methotrexate Injectable Solution",{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":501,"NA":503},{"trials":484,"activeCount":99},[],{"trials":486,"activeCount":99},[],{"trials":488,"activeCount":99},[],{"trials":490,"activeCount":95,"soonestReadout":495},[491],{"nctId":492,"briefTitle":493,"status":135,"phases":494,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":498,"interventions":500},"NCT07501507","Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual Treatments",[89,90],"2027-10","2026-05-02",170,[499],"Erosive Hand Osteoarthritis",[481],{"trials":502,"activeCount":99},[],{"trials":504,"activeCount":99},[],{"intervention":506,"totalTrials":95,"cells":507},"ISOtretinoin 5 MG",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":528,"NA":530},{"trials":509,"activeCount":99},[],{"trials":511,"activeCount":99},[],{"trials":513,"activeCount":99},[],{"trials":515,"activeCount":95,"soonestReadout":520},[516],{"nctId":517,"briefTitle":518,"status":180,"phases":519,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":524,"interventions":526},"NCT06447480","Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients",[90],"2026-09-01","2027-09-01","2025-04-29",420,[525],"Acne Vulgaris",[506,527],"Topical cream",{"trials":529,"activeCount":99},[],{"trials":531,"activeCount":99},[],{"intervention":527,"totalTrials":95,"cells":533},{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":546,"NA":548},{"trials":535,"activeCount":99},[],{"trials":537,"activeCount":99},[],{"trials":539,"activeCount":99},[],{"trials":541,"activeCount":95,"soonestReadout":520},[542],{"nctId":517,"briefTitle":518,"status":180,"phases":543,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":544,"interventions":545},[90],[525],[506,527],{"trials":547,"activeCount":99},[],{"trials":549,"activeCount":99},[],{"intervention":551,"totalTrials":348,"cells":552},"Deucravacitinib",{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":581,"PHASE4":583,"NA":585},{"trials":554,"activeCount":99},[],{"trials":556,"activeCount":99},[],{"trials":558,"activeCount":348,"soonestReadout":64},[559,570],{"nctId":560,"briefTitle":561,"status":109,"phases":562,"primaryCompletion":563,"completion":564,"start":565,"enrollment":566,"conditions":567,"interventions":569},"NCT06327321","Vitiligo Treatment by Targeting TYK2 Mediated Responses",[89],"2026-11-05","2027-07-05","2024-05-05",128,[568],"Vitiligo, Generalized",[551],{"nctId":62,"briefTitle":63,"status":180,"phases":571,"primaryCompletion":64,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":580},[89],"2026-10-12","2024-03-18",10,[576,577,578,579],"Epidermolysis Bullosa Simplex","Ichthyosis","Genodermatosis","Inflammatory Congenital Ichthyoses",[65],{"trials":582,"activeCount":99},[],{"trials":584,"activeCount":99},[],{"trials":586,"activeCount":99},[],{"intervention":70,"totalTrials":95,"cells":588},{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":593,"PHASE3":602,"PHASE4":604,"NA":606},{"trials":590,"activeCount":99},[],{"trials":592,"activeCount":99},[],{"trials":594,"activeCount":95,"soonestReadout":69},[595],{"nctId":67,"briefTitle":68,"status":180,"phases":596,"primaryCompletion":69,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":601},[89],"2026-04-01","2024-08-06",20,[576,578],[70],{"trials":603,"activeCount":99},[],{"trials":605,"activeCount":99},[],{"trials":607,"activeCount":99},[],{"intervention":609,"totalTrials":95,"cells":610},"Forxiga",{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":626,"PHASE4":628,"NA":630},{"trials":612,"activeCount":99},[],{"trials":614,"activeCount":99},[],{"trials":616,"activeCount":95,"soonestReadout":621},[617],{"nctId":618,"briefTitle":619,"status":135,"phases":620,"primaryCompletion":621,"completion":621,"start":622,"enrollment":599,"conditions":623,"interventions":625},"NCT07096986","Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy",[89],"2027-11","2025-11-01",[624],"Glomerulonephritis",[609],{"trials":627,"activeCount":99},[],{"trials":629,"activeCount":99},[],{"trials":631,"activeCount":99},[],{"intervention":633,"totalTrials":95,"cells":634},"Upadacitinib",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":651,"PHASE4":653,"NA":655},{"trials":636,"activeCount":99},[],{"trials":638,"activeCount":99},[],{"trials":640,"activeCount":95,"soonestReadout":645},[641],{"nctId":642,"briefTitle":643,"status":135,"phases":644,"primaryCompletion":645,"completion":646,"start":139,"enrollment":647,"conditions":648,"interventions":650},"NCT07492251","Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.",[89],"2028-02-01","2028-08-01",56,[649],"Lichen Penis Planus",[633],{"trials":652,"activeCount":99},[],{"trials":654,"activeCount":99},[],{"trials":656,"activeCount":99},[],{"intervention":658,"totalTrials":95,"cells":659},"Cytarabine and Idarubicin",{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":678,"PHASE4":680,"NA":682},{"trials":661,"activeCount":99},[],{"trials":663,"activeCount":99},[],{"trials":665,"activeCount":95,"soonestReadout":670},[666],{"nctId":667,"briefTitle":668,"status":180,"phases":669,"primaryCompletion":670,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":676},"NCT05260528","CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics",[89],"2028-08-02","2030-02-02","2023-05-03",248,[675],"Acute Myeloid Leukemia",[658,677],"CPX-315",{"trials":679,"activeCount":99},[],{"trials":681,"activeCount":99},[],{"trials":683,"activeCount":99},[],{"intervention":677,"totalTrials":95,"cells":685},{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":696,"PHASE4":698,"NA":700},{"trials":687,"activeCount":99},[],{"trials":689,"activeCount":99},[],{"trials":691,"activeCount":95,"soonestReadout":670},[692],{"nctId":667,"briefTitle":668,"status":180,"phases":693,"primaryCompletion":670,"completion":671,"start":672,"enrollment":673,"conditions":694,"interventions":695},[89],[675],[658,677],{"trials":697,"activeCount":99},[],{"trials":699,"activeCount":99},[],{"trials":701,"activeCount":99},[],{"intervention":703,"totalTrials":95,"cells":704},"Bimekizumab",{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":723,"PHASE4":725,"NA":727},{"trials":706,"activeCount":99},[],{"trials":708,"activeCount":99},[],{"trials":710,"activeCount":95,"soonestReadout":715},[711],{"nctId":712,"briefTitle":713,"status":180,"phases":714,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":721},"NCT06742333","Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?",[89],"2028-07-22","2029-01-01","2025-07-22",40,[720],"Psoriasis",[703,722],"Clobetasol",{"trials":724,"activeCount":99},[],{"trials":726,"activeCount":99},[],{"trials":728,"activeCount":99},[],{"intervention":722,"totalTrials":95,"cells":730},{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":741,"PHASE4":743,"NA":745},{"trials":732,"activeCount":99},[],{"trials":734,"activeCount":99},[],{"trials":736,"activeCount":95,"soonestReadout":715},[737],{"nctId":712,"briefTitle":713,"status":180,"phases":738,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":739,"interventions":740},[89],[720],[703,722],{"trials":742,"activeCount":99},[],{"trials":744,"activeCount":99},[],{"trials":746,"activeCount":99},[],{"intervention":748,"totalTrials":95,"cells":749},"Amiloride",{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":765,"PHASE4":767,"NA":769},{"trials":751,"activeCount":99},[],{"trials":753,"activeCount":99},[],{"trials":755,"activeCount":95,"soonestReadout":207},[756],{"nctId":757,"briefTitle":758,"status":180,"phases":759,"primaryCompletion":207,"completion":207,"start":760,"enrollment":718,"conditions":761,"interventions":763},"NCT04063540","Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura",[89],"2020-08-11",[762],"Migraine With Aura",[748,764],"Placebos",{"trials":766,"activeCount":99},[],{"trials":768,"activeCount":99},[],{"trials":770,"activeCount":99},[],{"intervention":764,"totalTrials":95,"cells":772},{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":783,"PHASE4":785,"NA":787},{"trials":774,"activeCount":99},[],{"trials":776,"activeCount":99},[],{"trials":778,"activeCount":95,"soonestReadout":207},[779],{"nctId":757,"briefTitle":758,"status":180,"phases":780,"primaryCompletion":207,"completion":207,"start":760,"enrollment":718,"conditions":781,"interventions":782},[89],[762],[748,764],{"trials":784,"activeCount":99},[],{"trials":786,"activeCount":99},[],{"trials":788,"activeCount":99},[],{"intervention":790,"totalTrials":95,"cells":791},"Satralizumab Prefilled Syringe",{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":796,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":793,"activeCount":99},[],{"trials":795,"activeCount":99},[],{"trials":797,"activeCount":95,"soonestReadout":277},[798],{"nctId":799,"briefTitle":800,"status":109,"phases":801,"primaryCompletion":277,"completion":277,"start":802,"enrollment":803,"conditions":804,"interventions":806},"NCT06222827","Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1",[89],"2024-01-24",46,[805],"Facioscapulohumeral Muscular Dystrophy 1",[790],{"trials":808,"activeCount":99},[],{"trials":810,"activeCount":99},[],{"trials":812,"activeCount":99},[],{"intervention":814,"totalTrials":95,"cells":815},"LITFULO",{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":820,"PHASE3":830,"PHASE4":832,"NA":834},{"trials":817,"activeCount":99},[],{"trials":819,"activeCount":99},[],{"trials":821,"activeCount":95,"soonestReadout":716},[822],{"nctId":823,"briefTitle":824,"status":180,"phases":825,"primaryCompletion":716,"completion":826,"start":827,"enrollment":647,"conditions":828,"interventions":829},"NCT07152626","Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo",[89],"2029-06-01","2026-03-12",[21],[814],{"trials":831,"activeCount":99},[],{"trials":833,"activeCount":99},[],{"trials":835,"activeCount":99},[],{"intervention":837,"totalTrials":95,"cells":838},"SKYCLARYS",{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":845,"PHASE4":847,"NA":849},{"trials":840,"activeCount":99},[],{"trials":842,"activeCount":99},[],{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":99},[],{"trials":848,"activeCount":99},[],{"trials":850,"activeCount":95,"soonestReadout":855},[851],{"nctId":852,"briefTitle":853,"status":180,"phases":854,"primaryCompletion":855,"completion":855,"start":856,"enrollment":718,"conditions":857,"interventions":859},"NCT07013292","Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's Ataxia",[],"2026-06-30","2025-06-01",[858],"Friedreich Ataxia",[837],{"intervention":45,"totalTrials":95,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":870,"NA":872},{"trials":863,"activeCount":99},[],{"trials":865,"activeCount":99},[],{"trials":867,"activeCount":99},[],{"trials":869,"activeCount":99},[],{"trials":871,"activeCount":99},[],{"trials":873,"activeCount":95,"soonestReadout":44},[874],{"nctId":42,"briefTitle":43,"status":109,"phases":875,"primaryCompletion":44,"completion":876,"start":877,"enrollment":878,"conditions":879,"interventions":881},[92],"2026-01-23","2021-05-18",15,[880],"Cystitis Recurrent",[45],{"intervention":883,"totalTrials":95,"cells":884},"paracetamol administration",{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":891,"PHASE4":893,"NA":895},{"trials":886,"activeCount":99},[],{"trials":888,"activeCount":99},[],{"trials":890,"activeCount":99},[],{"trials":892,"activeCount":99},[],{"trials":894,"activeCount":99},[],{"trials":896,"activeCount":95,"soonestReadout":901},[897],{"nctId":898,"briefTitle":899,"status":180,"phases":900,"primaryCompletion":901,"completion":902,"start":903,"enrollment":904,"conditions":905,"interventions":907},"NCT06430697","Hemodynamic Impact of the Administration of PAracetamol in Patients Hospitalized in the Intensive Resuscitation Medicine Department [PAREA]",[92],"2027-08","2028-09","2025-02-03",200,[906],"Intensive Care Unit Syndrome",[883],{"intervention":909,"totalTrials":95,"cells":910},"Cholestyramine Powder",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":912,"activeCount":99},[],{"trials":914,"activeCount":99},[],{"trials":916,"activeCount":99},[],{"trials":918,"activeCount":99},[],{"trials":920,"activeCount":99},[],{"trials":922,"activeCount":95,"soonestReadout":927},[923],{"nctId":924,"briefTitle":925,"status":180,"phases":926,"primaryCompletion":927,"completion":927,"start":928,"enrollment":599,"conditions":929,"interventions":933},"NCT05966727","Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients",[92],"2026-06-19","2025-03-19",[930,931,932],"Obesity, Abdominal","Diabetes","Bariatric Surgery Candidate",[909],{"intervention":935,"totalTrials":95,"cells":936},"Guselkumab",{"EARLY_PHASE1":937,"PHASE1":939,"PHASE2":941,"PHASE3":943,"PHASE4":945,"NA":947},{"trials":938,"activeCount":99},[],{"trials":940,"activeCount":99},[],{"trials":942,"activeCount":99},[],{"trials":944,"activeCount":99},[],{"trials":946,"activeCount":99},[],{"trials":948,"activeCount":95,"soonestReadout":953},[949],{"nctId":950,"briefTitle":951,"status":180,"phases":952,"primaryCompletion":953,"completion":953,"start":954,"enrollment":955,"conditions":956,"interventions":957},"NCT07430319","Real-Life Evaluation of Guselkumab Dosing Interval Adjustments",[],"2026-04-16","2025-10-16",100,[720],[935],{"intervention":959,"totalTrials":95,"cells":960},"capillary blood sampling",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":969,"NA":971},{"trials":962,"activeCount":99},[],{"trials":964,"activeCount":99},[],{"trials":966,"activeCount":99},[],{"trials":968,"activeCount":99},[],{"trials":970,"activeCount":99},[],{"trials":972,"activeCount":95,"soonestReadout":977},[973],{"nctId":974,"briefTitle":975,"status":180,"phases":976,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":981,"interventions":983},"NCT06969404","Prognostic Value of Capillary Lactatemia in Potentially Severe Polytrauma Patients",[92],"2027-06-15","2027-12-15","2026-02-07",550,[982],"Polytrauma",[959],{"intervention":985,"totalTrials":95,"cells":986},"switch of anti TNF for ustekinumab for paradoxical psoriasis.",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":988,"activeCount":99},[],{"trials":990,"activeCount":99},[],{"trials":992,"activeCount":99},[],{"trials":994,"activeCount":99},[],{"trials":996,"activeCount":99},[],{"trials":998,"activeCount":95,"soonestReadout":182},[999],{"nctId":1000,"briefTitle":1001,"status":135,"phases":1002,"primaryCompletion":182,"completion":182,"start":1003,"enrollment":718,"conditions":1004,"interventions":1006},"NCT07529236","Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to Ustekinumab Due to Paradoxical Psoriasis,",[],"2026-04-19",[1005],"Chronic Inflammatory Bowel Diseases",[985],{"intervention":1008,"totalTrials":95,"cells":1009},"Evaluation of cytokine production",{"EARLY_PHASE1":1010,"PHASE1":1012,"PHASE2":1014,"PHASE3":1016,"PHASE4":1018,"NA":1020},{"trials":1011,"activeCount":99},[],{"trials":1013,"activeCount":99},[],{"trials":1015,"activeCount":99},[],{"trials":1017,"activeCount":99},[],{"trials":1019,"activeCount":99},[],{"trials":1021,"activeCount":95,"soonestReadout":1026},[1022],{"nctId":1023,"briefTitle":1024,"status":180,"phases":1025,"primaryCompletion":1026,"completion":470,"start":1027,"enrollment":113,"conditions":1028,"interventions":1030},"NCT05649683","Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors",[92],"2027-02-01","2023-01-31",[1029],"Melanoma (Skin)",[1008],{"intervention":1032,"totalTrials":95,"cells":1033},"Gilteritinib",{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1040,"PHASE4":1042,"NA":1044},{"trials":1035,"activeCount":99},[],{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[],{"trials":1041,"activeCount":99},[],{"trials":1043,"activeCount":99},[],{"trials":1045,"activeCount":95,"soonestReadout":1050},[1046],{"nctId":1047,"briefTitle":1048,"status":135,"phases":1049,"primaryCompletion":1050,"completion":1050,"start":1051,"enrollment":574,"conditions":1052,"interventions":1054},"NCT06992934","Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors",[92],"2028-08","2025-08",[1053],"Hematological Malignancies",[1032],{"intervention":1056,"totalTrials":95,"cells":1057},"supplementary tubes",{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1062,"PHASE3":1064,"PHASE4":1066,"NA":1068},{"trials":1059,"activeCount":99},[],{"trials":1061,"activeCount":99},[],{"trials":1063,"activeCount":99},[],{"trials":1065,"activeCount":99},[],{"trials":1067,"activeCount":99},[],{"trials":1069,"activeCount":95,"soonestReadout":1074},[1070],{"nctId":1071,"briefTitle":1072,"status":180,"phases":1073,"primaryCompletion":1074,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1080},"NCT07323082","Purinergic Compounds in Pseudoxanthoma Elasticum",[92],"2027-01-15","2029-01-15","2026-01-20",45,[1079],"Pseudoxanthoma Elasticum",[1056],{"intervention":1082,"totalTrials":95,"cells":1083},"Premature neonates with invasive infection caused by Bacillus cereus",{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1090,"PHASE4":1092,"NA":1094},{"trials":1085,"activeCount":99},[],{"trials":1087,"activeCount":99},[],{"trials":1089,"activeCount":99},[],{"trials":1091,"activeCount":99},[],{"trials":1093,"activeCount":99},[],{"trials":1095,"activeCount":95,"soonestReadout":1100},[1096],{"nctId":1097,"briefTitle":1098,"status":180,"phases":1099,"primaryCompletion":1100,"completion":276,"start":1101,"enrollment":718,"conditions":1102,"interventions":1105},"NCT06973174","Bacillus Cereus Invasive Infections in Preterm Neonates Hospitalized in French Hospitals",[],"2026-07-30","2010-01-01",[1103,1104],"Sepsis","Infections",[1082],{"intervention":1107,"totalTrials":95,"cells":1108},"biopsy",{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1113,"PHASE3":1115,"PHASE4":1117,"NA":1119},{"trials":1110,"activeCount":99},[],{"trials":1112,"activeCount":99},[],{"trials":1114,"activeCount":99},[],{"trials":1116,"activeCount":99},[],{"trials":1118,"activeCount":99},[],{"trials":1120,"activeCount":95,"soonestReadout":1125},[1121],{"nctId":1122,"briefTitle":1123,"status":180,"phases":1124,"primaryCompletion":1125,"completion":1126,"start":1127,"enrollment":1128,"conditions":1129,"interventions":1131},"NCT07080333","MICROBIOTA AND BLADDER CANCER",[92],"2028-04-30","2028-10-30","2026-03-23",95,[1130],"Bladder (Urothelial, Transitional Cell) Cancer",[1107],{"intervention":40,"totalTrials":95,"cells":1133},{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1140,"PHASE4":1142,"NA":1144},{"trials":1135,"activeCount":99},[],{"trials":1137,"activeCount":99},[],{"trials":1139,"activeCount":99},[],{"trials":1141,"activeCount":99},[],{"trials":1143,"activeCount":99},[],{"trials":1145,"activeCount":95,"soonestReadout":39},[1146],{"nctId":37,"briefTitle":38,"status":180,"phases":1147,"primaryCompletion":39,"completion":1148,"start":39,"enrollment":1149,"conditions":1150,"interventions":1152},[],"2025-09-07",66,[1151],"Mitochondrial Diseases",[40],{"intervention":75,"totalTrials":95,"cells":1154},{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1159,"PHASE3":1161,"PHASE4":1163,"NA":1165},{"trials":1156,"activeCount":99},[],{"trials":1158,"activeCount":99},[],{"trials":1160,"activeCount":99},[],{"trials":1162,"activeCount":99},[],{"trials":1164,"activeCount":99},[],{"trials":1166,"activeCount":95,"soonestReadout":74},[1167],{"nctId":72,"briefTitle":73,"status":180,"phases":1168,"primaryCompletion":74,"completion":1169,"start":1170,"enrollment":904,"conditions":1171,"interventions":1173},[92],"2026-09","2024-12-06",[1172],"COVID Long-Haul",[75],{"intervention":85,"totalTrials":95,"cells":1175},{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1182,"PHASE4":1184,"NA":1186},{"trials":1177,"activeCount":99},[],{"trials":1179,"activeCount":99},[],{"trials":1181,"activeCount":99},[],{"trials":1183,"activeCount":99},[],{"trials":1185,"activeCount":99},[],{"trials":1187,"activeCount":95,"soonestReadout":84},[1188],{"nctId":82,"briefTitle":83,"status":180,"phases":1189,"primaryCompletion":84,"completion":1190,"start":1191,"enrollment":1192,"conditions":1193,"interventions":1195},[],"2026-03-03","2025-03-01",55,[1194],"Myasthenia Gravis",[85],{"intervention":1197,"totalTrials":95,"cells":1198},"Asparaginase-induced in vitro T-cell stimulation",{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1200,"activeCount":99},[],{"trials":1202,"activeCount":99},[],{"trials":1204,"activeCount":99},[],{"trials":1206,"activeCount":99},[],{"trials":1208,"activeCount":99},[],{"trials":1210,"activeCount":95,"soonestReadout":1215},[1211],{"nctId":1212,"briefTitle":1213,"status":135,"phases":1214,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":599,"conditions":1217,"interventions":1219},"NCT07529223","Role of T Lymphocytes in Hypersensitivity Reactions to Asparaginase in Patients Treated for Acute Lymphoblastic Leukemia.",[92],"2027-04-30","2026-04-30",[1218],"Acute Lymphoblastic Leukemia ALL",[1197],{"intervention":80,"totalTrials":95,"cells":1221},{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1226,"PHASE3":1228,"PHASE4":1230,"NA":1232},{"trials":1223,"activeCount":99},[],{"trials":1225,"activeCount":99},[],{"trials":1227,"activeCount":99},[],{"trials":1229,"activeCount":99},[],{"trials":1231,"activeCount":99},[],{"trials":1233,"activeCount":95,"soonestReadout":79},[1234],{"nctId":77,"briefTitle":78,"status":109,"phases":1235,"primaryCompletion":79,"completion":1236,"start":1237,"enrollment":955,"conditions":1238,"interventions":1240},[92],"2027-03-01","2023-12-05",[1239],"Allergic Bronchiolitis",[80],{"intervention":1242,"totalTrials":348,"cells":1243},"sedation with propofol",{"EARLY_PHASE1":1244,"PHASE1":1246,"PHASE2":1248,"PHASE3":1250,"PHASE4":1261,"NA":1272},{"trials":1245,"activeCount":99},[],{"trials":1247,"activeCount":99},[],{"trials":1249,"activeCount":99},[],{"trials":1251,"activeCount":99},[1252],{"nctId":1253,"briefTitle":1254,"status":359,"phases":1255,"primaryCompletion":1256,"completion":1256,"start":1257,"enrollment":599,"conditions":1258,"interventions":1260},"NCT02734511","Efficiency and Safety of a Procedural Sedation by Propofol on Terminally Ill Patients With Refractory Pain",[90],"2019-09-26","2017-05-19",[1259],"Refractory Pains",[1242],{"trials":1262,"activeCount":99},[1263],{"nctId":1264,"briefTitle":1265,"status":359,"phases":1266,"primaryCompletion":1267,"completion":1267,"start":1268,"enrollment":574,"conditions":1269,"interventions":1271},"NCT02198404","Pilot Study of Sedation With Propofol in Refractory Pains Due to Care in Palliative Care Unit",[91],"2015-09-29","2014-06-20",[1259,1270],"End of Life Patients",[1242],{"trials":1273,"activeCount":99},[],{"intervention":1275,"totalTrials":95,"cells":1276},"Ceftriaxone",{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1283,"PHASE4":1285,"NA":1297},{"trials":1278,"activeCount":99},[],{"trials":1280,"activeCount":99},[],{"trials":1282,"activeCount":99},[],{"trials":1284,"activeCount":99},[],{"trials":1286,"activeCount":99},[1287],{"nctId":1288,"briefTitle":1289,"status":359,"phases":1290,"primaryCompletion":1291,"completion":1291,"start":1292,"enrollment":1293,"conditions":1294,"interventions":1296},"NCT03179384","Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis",[91],"2019-02-05","2017-06-26",9,[1295],"Pyelonephritis Acute",[1275],{"trials":1298,"activeCount":99},[],{"intervention":1300,"totalTrials":95,"cells":1301},"Smoflipid",{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1308,"PHASE4":1310,"NA":1322},{"trials":1303,"activeCount":99},[],{"trials":1305,"activeCount":99},[],{"trials":1307,"activeCount":99},[],{"trials":1309,"activeCount":99},[],{"trials":1311,"activeCount":99},[1312],{"nctId":1313,"briefTitle":1314,"status":359,"phases":1315,"primaryCompletion":1316,"completion":1316,"start":1317,"enrollment":1293,"conditions":1318,"interventions":1320},"NCT02539316","Pilot Study: Hepatoprotective Role of SMOFlipid® Used in Short-term Parenteral Nutrition in an Onco-Hematology Pediatric Population",[91],"2016-10","2015-06",[1319],"Dietary and Nutritional Therapies",[1300,1321],"Médialipides",{"trials":1323,"activeCount":99},[],{"intervention":1321,"totalTrials":95,"cells":1325},{"EARLY_PHASE1":1326,"PHASE1":1328,"PHASE2":1330,"PHASE3":1332,"PHASE4":1334,"NA":1340},{"trials":1327,"activeCount":99},[],{"trials":1329,"activeCount":99},[],{"trials":1331,"activeCount":99},[],{"trials":1333,"activeCount":99},[],{"trials":1335,"activeCount":99},[1336],{"nctId":1313,"briefTitle":1314,"status":359,"phases":1337,"primaryCompletion":1316,"completion":1316,"start":1317,"enrollment":1293,"conditions":1338,"interventions":1339},[91],[1319],[1300,1321],{"trials":1341,"activeCount":99},[],{"intervention":1343,"totalTrials":95,"cells":1344},"Sufentanil",{"EARLY_PHASE1":1345,"PHASE1":1347,"PHASE2":1349,"PHASE3":1351,"PHASE4":1353,"NA":1365},{"trials":1346,"activeCount":99},[],{"trials":1348,"activeCount":99},[],{"trials":1350,"activeCount":99},[],{"trials":1352,"activeCount":99},[],{"trials":1354,"activeCount":99},[1355],{"nctId":1356,"briefTitle":1357,"status":359,"phases":1358,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1361,"conditions":1362,"interventions":1364},"NCT01954368","Intranasal Sufentanil Pain-management at Entrance of Emergency Department : Influence on Pain-relief Delay",[91],"2016-03","2014-01",144,[1363],"Single Traumatic Limb Injury With Severe Pain (Score > 5\u002F10 on Numerical Pain Scale)",[1343],{"trials":1366,"activeCount":99},[],{"intervention":1368,"totalTrials":95,"cells":1369},"Kligman's Trio",{"EARLY_PHASE1":1370,"PHASE1":1372,"PHASE2":1374,"PHASE3":1376,"PHASE4":1378,"NA":1391},{"trials":1371,"activeCount":99},[],{"trials":1373,"activeCount":99},[],{"trials":1375,"activeCount":99},[],{"trials":1377,"activeCount":99},[],{"trials":1379,"activeCount":99},[1380],{"nctId":1381,"briefTitle":1382,"status":1383,"phases":1384,"primaryCompletion":1385,"completion":1386,"start":1387,"enrollment":599,"conditions":1388,"interventions":1390},"NCT00863278","Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser","TERMINATED",[91],"2010-03","2010-12","2009-03",[1389],"Melanosis",[1368],{"trials":1392,"activeCount":99},[],{"intervention":1394,"totalTrials":95,"cells":1395},"Advagraf",{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1400,"PHASE3":1402,"PHASE4":1404,"NA":1417},{"trials":1397,"activeCount":99},[],{"trials":1399,"activeCount":99},[],{"trials":1401,"activeCount":99},[],{"trials":1403,"activeCount":99},[],{"trials":1405,"activeCount":99},[1406],{"nctId":1407,"briefTitle":1408,"status":359,"phases":1409,"primaryCompletion":1410,"completion":1411,"start":1412,"enrollment":1077,"conditions":1413,"interventions":1415},"NCT01435291","AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation",[91],"2013-05","2013-07","2011-10",[1414],"Renal Transplantation",[1394,1416],"Prograf",{"trials":1418,"activeCount":99},[],{"intervention":1416,"totalTrials":95,"cells":1420},{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1427,"PHASE4":1429,"NA":1435},{"trials":1422,"activeCount":99},[],{"trials":1424,"activeCount":99},[],{"trials":1426,"activeCount":99},[],{"trials":1428,"activeCount":99},[],{"trials":1430,"activeCount":99},[1431],{"nctId":1407,"briefTitle":1408,"status":359,"phases":1432,"primaryCompletion":1410,"completion":1411,"start":1412,"enrollment":1077,"conditions":1433,"interventions":1434},[91],[1414],[1394,1416],{"trials":1436,"activeCount":99},[],{"intervention":1438,"totalTrials":95,"cells":1439},"zometa",{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1444,"PHASE3":1446,"PHASE4":1448,"NA":1461},{"trials":1441,"activeCount":99},[],{"trials":1443,"activeCount":99},[],{"trials":1445,"activeCount":99},[],{"trials":1447,"activeCount":99},[],{"trials":1449,"activeCount":99},[1450],{"nctId":1451,"briefTitle":1452,"status":359,"phases":1453,"primaryCompletion":1454,"completion":1455,"start":1456,"enrollment":1457,"conditions":1458,"interventions":1460},"NCT00733538","Stage I Multiple Myeloma Treatment",[91],"2009-11","2012-11","2004-12",89,[1459],"Multiple Myeloma",[1438],{"trials":1462,"activeCount":99},[],{"intervention":1464,"totalTrials":95,"cells":1465},"Furosemide",{"EARLY_PHASE1":1466,"PHASE1":1468,"PHASE2":1470,"PHASE3":1472,"PHASE4":1474,"NA":1486},{"trials":1467,"activeCount":99},[],{"trials":1469,"activeCount":99},[],{"trials":1471,"activeCount":99},[],{"trials":1473,"activeCount":99},[],{"trials":1475,"activeCount":99},[1476],{"nctId":1477,"briefTitle":1478,"status":359,"phases":1479,"primaryCompletion":1480,"completion":1480,"start":1481,"enrollment":113,"conditions":1482,"interventions":1484},"NCT02531581","Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive",[91],"2020-04-09","2015-12-23",[1483],"Pulmonary Embolism",[1464,1485],"NaCl 9% isotonic",{"trials":1487,"activeCount":99},[],{"intervention":1485,"totalTrials":95,"cells":1489},{"EARLY_PHASE1":1490,"PHASE1":1492,"PHASE2":1494,"PHASE3":1496,"PHASE4":1498,"NA":1504},{"trials":1491,"activeCount":99},[],{"trials":1493,"activeCount":99},[],{"trials":1495,"activeCount":99},[],{"trials":1497,"activeCount":99},[],{"trials":1499,"activeCount":99},[1500],{"nctId":1477,"briefTitle":1478,"status":359,"phases":1501,"primaryCompletion":1480,"completion":1480,"start":1481,"enrollment":113,"conditions":1502,"interventions":1503},[91],[1483],[1464,1485],{"trials":1505,"activeCount":99},[],{"intervention":1507,"totalTrials":95,"cells":1508},"Procedural sedation with ketamine-propofol combination",{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1513,"PHASE3":1515,"PHASE4":1517,"NA":1530},{"trials":1510,"activeCount":99},[],{"trials":1512,"activeCount":99},[],{"trials":1514,"activeCount":99},[],{"trials":1516,"activeCount":99},[],{"trials":1518,"activeCount":99},[1519],{"nctId":1520,"briefTitle":1521,"status":359,"phases":1522,"primaryCompletion":1523,"completion":1523,"start":1524,"enrollment":279,"conditions":1525,"interventions":1528},"NCT01544725","Ketamine-propofol Versus Ketamine Alone for Procedural Sedation in Adults",[91],"2016-01","2012-04",[1526,1527],"Fracture","Dislocation",[1507,1529],"Procedural sedation with ketamine alone",{"trials":1531,"activeCount":99},[],{"intervention":1529,"totalTrials":95,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1540,"PHASE4":1542,"NA":1548},{"trials":1535,"activeCount":99},[],{"trials":1537,"activeCount":99},[],{"trials":1539,"activeCount":99},[],{"trials":1541,"activeCount":99},[],{"trials":1543,"activeCount":99},[1544],{"nctId":1520,"briefTitle":1521,"status":359,"phases":1545,"primaryCompletion":1523,"completion":1523,"start":1524,"enrollment":279,"conditions":1546,"interventions":1547},[91],[1526,1527],[1507,1529],{"trials":1549,"activeCount":99},[],{"intervention":1551,"totalTrials":95,"cells":1552},"Esketamine",{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1559,"PHASE4":1561,"NA":1574},{"trials":1554,"activeCount":99},[],{"trials":1556,"activeCount":99},[],{"trials":1558,"activeCount":99},[],{"trials":1560,"activeCount":99},[],{"trials":1562,"activeCount":99},[1563],{"nctId":1564,"briefTitle":1565,"status":359,"phases":1566,"primaryCompletion":1567,"completion":1567,"start":1568,"enrollment":1569,"conditions":1570,"interventions":1572},"NCT06853041","ESKetamine Low-dose vs Ketamine Low-dose for Severe Acute Pain in Emergency Units, Comparison of PsychodyslEptic Effects",[91],"2026-05-05","2025-05-06",74,[1571],"Acute Pain",[1551,1573],"Ketamine",{"trials":1575,"activeCount":99},[],{"intervention":1573,"totalTrials":95,"cells":1577},{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1582,"PHASE3":1584,"PHASE4":1586,"NA":1592},{"trials":1579,"activeCount":99},[],{"trials":1581,"activeCount":99},[],{"trials":1583,"activeCount":99},[],{"trials":1585,"activeCount":99},[],{"trials":1587,"activeCount":99},[1588],{"nctId":1564,"briefTitle":1565,"status":359,"phases":1589,"primaryCompletion":1567,"completion":1567,"start":1568,"enrollment":1569,"conditions":1590,"interventions":1591},[91],[1571],[1551,1573],{"trials":1593,"activeCount":99},[],{"intervention":1595,"totalTrials":95,"cells":1596},"LEVOTHYROXINE",{"EARLY_PHASE1":1597,"PHASE1":1599,"PHASE2":1601,"PHASE3":1603,"PHASE4":1605,"NA":1617},{"trials":1598,"activeCount":99},[],{"trials":1600,"activeCount":99},[],{"trials":1602,"activeCount":99},[],{"trials":1604,"activeCount":99},[],{"trials":1606,"activeCount":99},[1607],{"nctId":1608,"briefTitle":1609,"status":1610,"phases":1611,"primaryCompletion":1316,"completion":1612,"start":1613,"enrollment":99,"conditions":1614,"interventions":1616},"NCT02186405","Effects of Levothyroxine Treatment on Hemodynamic and Renal Functions in Subclinical Hypothyroidism","WITHDRAWN",[91],"2017-06","2015-10",[1615],"Subclinical hypothyroïdism",[1595],{"trials":1618,"activeCount":99},[],{"intervention":1620,"totalTrials":95,"cells":1621},"Target control infusion with propofol",{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1628,"PHASE4":1630,"NA":1642},{"trials":1623,"activeCount":99},[],{"trials":1625,"activeCount":99},[],{"trials":1627,"activeCount":99},[],{"trials":1629,"activeCount":99},[],{"trials":1631,"activeCount":99},[1632],{"nctId":1633,"briefTitle":1634,"status":359,"phases":1635,"primaryCompletion":1636,"completion":1636,"start":1637,"enrollment":1077,"conditions":1638,"interventions":1641},"NCT03783494","Target-controlled Infusion With Propofol in the Emergency Department : a Prospective Study on 45 Adult Patients",[91],"2020-10-25","2019-05-09",[1639,1640],"Joint Dislocation","Limb Fracture",[1620],{"trials":1643,"activeCount":99},[],{"intervention":1645,"totalTrials":95,"cells":1646},"Methotrexate",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1653,"PHASE4":1665,"NA":1667},{"trials":1648,"activeCount":99},[],{"trials":1650,"activeCount":99},[],{"trials":1652,"activeCount":99},[],{"trials":1654,"activeCount":99},[1655],{"nctId":1656,"briefTitle":1657,"status":1658,"phases":1659,"primaryCompletion":1660,"completion":1660,"start":1385,"enrollment":1661,"conditions":1662,"interventions":1664},"NCT01068405","Erosive Osteoarthritis of the Hands: Treatment by Methotrexate Versus Placebo","UNKNOWN",[90],"2012-03",64,[1663],"Polyarthritis",[1645],{"trials":1666,"activeCount":99},[],{"trials":1668,"activeCount":99},[],{"intervention":1670,"totalTrials":95,"cells":1671},"Lidocaine = group A",{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1678,"PHASE4":1692,"NA":1694},{"trials":1673,"activeCount":99},[],{"trials":1675,"activeCount":99},[],{"trials":1677,"activeCount":99},[],{"trials":1679,"activeCount":99},[1680],{"nctId":1681,"briefTitle":1682,"status":359,"phases":1683,"primaryCompletion":1684,"completion":1685,"start":1686,"enrollment":1687,"conditions":1688,"interventions":1690},"NCT02022059","Prospective Monocentric Study on the Efficacy of Lidocain Spray for Patient Comfort During Nasogastric Tube Insertion in Enteral Nutrition",[90],"2018-04","2019-05-24","2013-12",61,[1689],"Undernutrition",[1670,1691],"Group B placebo",{"trials":1693,"activeCount":99},[],{"trials":1695,"activeCount":99},[],{"intervention":1691,"totalTrials":95,"cells":1697},{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1702,"PHASE3":1704,"PHASE4":1710,"NA":1712},{"trials":1699,"activeCount":99},[],{"trials":1701,"activeCount":99},[],{"trials":1703,"activeCount":99},[],{"trials":1705,"activeCount":99},[1706],{"nctId":1681,"briefTitle":1682,"status":359,"phases":1707,"primaryCompletion":1684,"completion":1685,"start":1686,"enrollment":1687,"conditions":1708,"interventions":1709},[90],[1689],[1670,1691],{"trials":1711,"activeCount":99},[],{"trials":1713,"activeCount":99},[],{"intervention":1715,"totalTrials":95,"cells":1716},"Protopic",{"EARLY_PHASE1":1717,"PHASE1":1719,"PHASE2":1721,"PHASE3":1723,"PHASE4":1736,"NA":1738},{"trials":1718,"activeCount":99},[],{"trials":1720,"activeCount":99},[],{"trials":1722,"activeCount":99},[],{"trials":1724,"activeCount":99},[1725],{"nctId":1726,"briefTitle":1727,"status":1383,"phases":1728,"primaryCompletion":1729,"completion":1730,"start":1731,"enrollment":1732,"conditions":1733,"interventions":1735},"NCT01841008","Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control",[89,90],"2013-06","2014-06","2011-12",35,[1734,21],"Pigmentation Disorders",[1715],{"trials":1737,"activeCount":99},[],{"trials":1739,"activeCount":99},[],{"intervention":1741,"totalTrials":95,"cells":1742},"Aflibercept",{"EARLY_PHASE1":1743,"PHASE1":1745,"PHASE2":1747,"PHASE3":1749,"PHASE4":1762,"NA":1764},{"trials":1744,"activeCount":99},[],{"trials":1746,"activeCount":99},[],{"trials":1748,"activeCount":99},[],{"trials":1750,"activeCount":99},[1751],{"nctId":1752,"briefTitle":1753,"status":359,"phases":1754,"primaryCompletion":1755,"completion":1755,"start":1756,"enrollment":1757,"conditions":1758,"interventions":1760},"NCT03172299","Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma",[90],"2025-01-31","2017-06-08",57,[1759],"Ocular Melanoma",[1741,1761],"False",{"trials":1763,"activeCount":99},[],{"trials":1765,"activeCount":99},[],{"intervention":1761,"totalTrials":95,"cells":1767},{"EARLY_PHASE1":1768,"PHASE1":1770,"PHASE2":1772,"PHASE3":1774,"PHASE4":1780,"NA":1782},{"trials":1769,"activeCount":99},[],{"trials":1771,"activeCount":99},[],{"trials":1773,"activeCount":99},[],{"trials":1775,"activeCount":99},[1776],{"nctId":1752,"briefTitle":1753,"status":359,"phases":1777,"primaryCompletion":1755,"completion":1755,"start":1756,"enrollment":1757,"conditions":1778,"interventions":1779},[90],[1759],[1741,1761],{"trials":1781,"activeCount":99},[],{"trials":1783,"activeCount":99},[],{"intervention":1785,"totalTrials":95,"cells":1786},"Timolol + LCP",{"EARLY_PHASE1":1787,"PHASE1":1789,"PHASE2":1791,"PHASE3":1793,"PHASE4":1804,"NA":1806},{"trials":1788,"activeCount":99},[],{"trials":1790,"activeCount":99},[],{"trials":1792,"activeCount":99},[],{"trials":1794,"activeCount":99},[1795],{"nctId":1796,"briefTitle":1797,"status":1658,"phases":1798,"primaryCompletion":1799,"completion":1800,"start":1799,"enrollment":1801,"conditions":1802,"interventions":1803},"NCT01272609","Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel",[90],"2011-01","2012-05",44,[33],[1785],{"trials":1805,"activeCount":99},[],{"trials":1807,"activeCount":99},[],{"intervention":1809,"totalTrials":95,"cells":1810},"Teriflunomide",{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1815,"PHASE3":1817,"PHASE4":1828,"NA":1830},{"trials":1812,"activeCount":99},[],{"trials":1814,"activeCount":99},[],{"trials":1816,"activeCount":99},[],{"trials":1818,"activeCount":99},[1819],{"nctId":1820,"briefTitle":1821,"status":359,"phases":1822,"primaryCompletion":1823,"completion":1824,"start":1825,"enrollment":472,"conditions":1826,"interventions":1827},"NCT02587195","A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period",[90],"2020-08-31","2021-08-31","2015-12-18",[18],[1809],{"trials":1829,"activeCount":99},[],{"trials":1831,"activeCount":99},[],{"intervention":1833,"totalTrials":95,"cells":1834},"Antiviral treatment with conventional non-surgical treatment",{"EARLY_PHASE1":1835,"PHASE1":1837,"PHASE2":1839,"PHASE3":1841,"PHASE4":1853,"NA":1855},{"trials":1836,"activeCount":99},[],{"trials":1838,"activeCount":99},[],{"trials":1840,"activeCount":99},[],{"trials":1842,"activeCount":99},[1843],{"nctId":1844,"briefTitle":1845,"status":1658,"phases":1846,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1849,"conditions":1850,"interventions":1852},"NCT05902208","Contribution of an Antiviral Drug (Valaciclovir) in the Treatment of Generalized Periodontitis (Stage III or IV and Grade A, B or C): Prospective, Randomized and Double Blind Clinical Trial",[90],"2026-05","2024-02-05",142,[1851],"Periodontitis Chronic Generalized Severe",[1833],{"trials":1854,"activeCount":99},[],{"trials":1856,"activeCount":99},[],{"intervention":1858,"totalTrials":95,"cells":1859},"apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side",{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1866,"PHASE4":1877,"NA":1879},{"trials":1861,"activeCount":99},[],{"trials":1863,"activeCount":99},[],{"trials":1865,"activeCount":99},[],{"trials":1867,"activeCount":99},[1868],{"nctId":1869,"briefTitle":1870,"status":1658,"phases":1871,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":24,"conditions":1874,"interventions":1876},"NCT01222000","Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous",[90],"2011-06","2010-10",[1875],"Lamellar Ichthyosis",[1858,1858],{"trials":1878,"activeCount":99},[],{"trials":1880,"activeCount":99},[],{"intervention":1882,"totalTrials":95,"cells":1883},"Bras B : The group control",{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1888,"PHASE3":1890,"PHASE4":1899,"NA":1901},{"trials":1885,"activeCount":99},[],{"trials":1887,"activeCount":99},[],{"trials":1889,"activeCount":99},[],{"trials":1891,"activeCount":99},[1892],{"nctId":1893,"briefTitle":1894,"status":359,"phases":1895,"primaryCompletion":1385,"completion":1896,"start":1385,"enrollment":599,"conditions":1897,"interventions":1898},"NCT01087216","Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo",[89,90],"2011-03",[21],[1882],{"trials":1900,"activeCount":99},[],{"trials":1902,"activeCount":99},[],{"intervention":1904,"totalTrials":95,"cells":1905},"Autologous platelets gel",{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1910,"PHASE3":1912,"PHASE4":1924,"NA":1926},{"trials":1907,"activeCount":99},[],{"trials":1909,"activeCount":99},[],{"trials":1911,"activeCount":99},[],{"trials":1913,"activeCount":99},[1914],{"nctId":1915,"briefTitle":1916,"status":359,"phases":1917,"primaryCompletion":1918,"completion":1918,"start":1919,"enrollment":1920,"conditions":1921,"interventions":1923},"NCT00931567","Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing",[89,90],"2010-02","2007-08",80,[1922],"Dupuytren's Contracture",[1904],{"trials":1925,"activeCount":99},[],{"trials":1927,"activeCount":99},[],{"intervention":1929,"totalTrials":95,"cells":1930},"Molar Sodium Lactate",{"EARLY_PHASE1":1931,"PHASE1":1933,"PHASE2":1935,"PHASE3":1937,"PHASE4":1951,"NA":1953},{"trials":1932,"activeCount":99},[],{"trials":1934,"activeCount":99},[],{"trials":1936,"activeCount":99},[],{"trials":1938,"activeCount":99},[1939],{"nctId":1940,"briefTitle":1941,"status":1383,"phases":1942,"primaryCompletion":1943,"completion":1944,"start":1945,"enrollment":1946,"conditions":1947,"interventions":1949},"NCT04141371","Molar Sodium Lactate Filling in Severe Meningeal Hemorrhage",[90],"2022-05-05","2024-06-07","2022-02-14",3,[1948],"Subarachnoid Hemorrhage, Aneurysmal",[1929,1950],"physiological serum",{"trials":1952,"activeCount":99},[],{"trials":1954,"activeCount":99},[],{"intervention":1950,"totalTrials":95,"cells":1956},{"EARLY_PHASE1":1957,"PHASE1":1959,"PHASE2":1961,"PHASE3":1963,"PHASE4":1969,"NA":1971},{"trials":1958,"activeCount":99},[],{"trials":1960,"activeCount":99},[],{"trials":1962,"activeCount":99},[],{"trials":1964,"activeCount":99},[1965],{"nctId":1940,"briefTitle":1941,"status":1383,"phases":1966,"primaryCompletion":1943,"completion":1944,"start":1945,"enrollment":1946,"conditions":1967,"interventions":1968},[90],[1948],[1929,1950],{"trials":1970,"activeCount":99},[],{"trials":1972,"activeCount":99},[],{"intervention":1974,"totalTrials":95,"cells":1975},"Oral erythromycin",{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1982,"PHASE4":1992,"NA":1994},{"trials":1977,"activeCount":99},[],{"trials":1979,"activeCount":99},[],{"trials":1981,"activeCount":99},[],{"trials":1983,"activeCount":99},[1984],{"nctId":1985,"briefTitle":1986,"status":1658,"phases":1987,"primaryCompletion":1731,"completion":1988,"start":1872,"enrollment":24,"conditions":1989,"interventions":1991},"NCT01340235","Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin",[90],"2012-06",[1990],"Epidermolysis Bullosa",[1974],{"trials":1993,"activeCount":99},[],{"trials":1995,"activeCount":99},[],{"intervention":1997,"totalTrials":95,"cells":1998},"treatment",{"EARLY_PHASE1":1999,"PHASE1":2001,"PHASE2":2003,"PHASE3":2005,"PHASE4":2017,"NA":2019},{"trials":2000,"activeCount":99},[],{"trials":2002,"activeCount":99},[],{"trials":2004,"activeCount":99},[],{"trials":2006,"activeCount":99},[2007],{"nctId":2008,"briefTitle":2009,"status":1658,"phases":2010,"primaryCompletion":2011,"completion":2012,"start":2011,"enrollment":24,"conditions":2013,"interventions":2016},"NCT03841734","Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO",[90],"2019-03","2021-03",[2014,2015],"Arteritis, Giant Cell","Blindness and Low Vision",[1997],{"trials":2018,"activeCount":99},[],{"trials":2020,"activeCount":99},[],{"intervention":2022,"totalTrials":95,"cells":2023},"IL2",{"EARLY_PHASE1":2024,"PHASE1":2026,"PHASE2":2028,"PHASE3":2030,"PHASE4":2042,"NA":2044},{"trials":2025,"activeCount":99},[],{"trials":2027,"activeCount":99},[],{"trials":2029,"activeCount":99},[],{"trials":2031,"activeCount":99},[2032],{"nctId":2033,"briefTitle":2034,"status":359,"phases":2035,"primaryCompletion":2036,"completion":2037,"start":2038,"enrollment":1801,"conditions":2039,"interventions":2041},"NCT02557074","TREg Activation in the Treatment of the PELADE (Alopecia Areata)",[90],"2019-02-02","2019-12-02","2015-12-15",[2040],"Alopecia Areata",[2022],{"trials":2043,"activeCount":99},[],{"trials":2045,"activeCount":99},[],{"intervention":2047,"totalTrials":95,"cells":2048},"Teriflunomide 14 MG Oral Tablet [Aubagio]",{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2055,"PHASE4":2066,"NA":2068},{"trials":2050,"activeCount":99},[],{"trials":2052,"activeCount":99},[],{"trials":2054,"activeCount":99},[],{"trials":2056,"activeCount":99},[2057],{"nctId":2058,"briefTitle":2059,"status":359,"phases":2060,"primaryCompletion":1291,"completion":2061,"start":2062,"enrollment":2063,"conditions":2064,"interventions":2065},"NCT03122652","Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome",[90],"2022-10-04","2017-09-25",125,[18],[2047],{"trials":2067,"activeCount":99},[],{"trials":2069,"activeCount":99},[],{"intervention":2071,"totalTrials":95,"cells":2072},"Amantadin",{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2079,"PHASE4":2089,"NA":2091},{"trials":2074,"activeCount":99},[],{"trials":2076,"activeCount":99},[],{"trials":2078,"activeCount":99},[],{"trials":2080,"activeCount":99},[2081],{"nctId":2082,"briefTitle":2083,"status":359,"phases":2084,"primaryCompletion":2085,"completion":2085,"start":1387,"enrollment":184,"conditions":2086,"interventions":2088},"NCT00821691","Action of Amantadine on Post-Stroke Aphasic Patients",[89,90],"2013-04",[2087],"Cerebral Infarction",[2071],{"trials":2090,"activeCount":99},[],{"trials":2092,"activeCount":99},[],{"intervention":2094,"totalTrials":95,"cells":2095},"Nivolumab",{"EARLY_PHASE1":2096,"PHASE1":2098,"PHASE2":2100,"PHASE3":2110,"PHASE4":2112,"NA":2114},{"trials":2097,"activeCount":99},[],{"trials":2099,"activeCount":99},[],{"trials":2101,"activeCount":99},[2102],{"nctId":2103,"briefTitle":2104,"status":359,"phases":2105,"primaryCompletion":2106,"completion":2106,"start":2107,"enrollment":404,"conditions":2108,"interventions":2109},"NCT02799901","Nivolumab Plus Radiotherapy in Advanced Melanoma",[89],"2021-07-28","2017-03-03",[33],[2094],{"trials":2111,"activeCount":99},[],{"trials":2113,"activeCount":99},[],{"trials":2115,"activeCount":99},[],{"intervention":2117,"totalTrials":95,"cells":2118},"Bosentan",{"EARLY_PHASE1":2119,"PHASE1":2121,"PHASE2":2123,"PHASE3":2136,"PHASE4":2138,"NA":2140},{"trials":2120,"activeCount":99},[],{"trials":2122,"activeCount":99},[],{"trials":2124,"activeCount":99},[2125],{"nctId":2126,"briefTitle":2127,"status":359,"phases":2128,"primaryCompletion":2129,"completion":2130,"start":2131,"enrollment":2132,"conditions":2133,"interventions":2135},"NCT02317679","Treatment of Resistant Port-wine Stains With Bosentan and Pulsed Dye Laser: a Pilot Study",[89],"2014-09","2015-02","2014-04",4,[2134],"Port-wine Stains",[2117],{"trials":2137,"activeCount":99},[],{"trials":2139,"activeCount":99},[],{"trials":2141,"activeCount":99},[],{"intervention":2143,"totalTrials":95,"cells":2144},"Betamethasone-Calcipotriene Topical",{"EARLY_PHASE1":2145,"PHASE1":2147,"PHASE2":2149,"PHASE3":2161,"PHASE4":2163,"NA":2165},{"trials":2146,"activeCount":99},[],{"trials":2148,"activeCount":99},[],{"trials":2150,"activeCount":99},[2151],{"nctId":2152,"briefTitle":2153,"status":359,"phases":2154,"primaryCompletion":2155,"completion":2156,"start":2155,"enrollment":2157,"conditions":2158,"interventions":2160},"NCT03584360","Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin",[89],"2018-09-24","2019-03-07",30,[2159],"Psoriasis Vulgaris",[2143,2143,2143],{"trials":2162,"activeCount":99},[],{"trials":2164,"activeCount":99},[],{"trials":2166,"activeCount":99},[],{"intervention":2168,"totalTrials":95,"cells":2169},"Picato 0.05% Topical Gel",{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2174,"PHASE3":2187,"PHASE4":2189,"NA":2191},{"trials":2171,"activeCount":99},[],{"trials":2173,"activeCount":99},[],{"trials":2175,"activeCount":99},[2176],{"nctId":2177,"briefTitle":2178,"status":359,"phases":2179,"primaryCompletion":2180,"completion":2181,"start":2182,"enrollment":2183,"conditions":2184,"interventions":2186},"NCT03546166","Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma",[89],"2021-03-11","2022-03-11","2018-07-26",24,[2185],"Carcinoma",[2168],{"trials":2188,"activeCount":99},[],{"trials":2190,"activeCount":99},[],{"trials":2192,"activeCount":99},[],{"intervention":2194,"totalTrials":95,"cells":2195},"Interleukin-2",{"EARLY_PHASE1":2196,"PHASE1":2198,"PHASE2":2200,"PHASE3":2208,"PHASE4":2210,"NA":2212},{"trials":2197,"activeCount":99},[],{"trials":2199,"activeCount":99},[],{"trials":2201,"activeCount":99},[2202],{"nctId":2203,"briefTitle":2204,"status":1383,"phases":2205,"primaryCompletion":1455,"completion":1410,"start":1455,"enrollment":2132,"conditions":2206,"interventions":2207},"NCT01840046","Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata",[88,89],[2040],[2194],{"trials":2209,"activeCount":99},[],{"trials":2211,"activeCount":99},[],{"trials":2213,"activeCount":99},[],{"intervention":2215,"totalTrials":95,"cells":2216},"Tirbanibulin",{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2221,"PHASE3":2233,"PHASE4":2235,"NA":2237},{"trials":2218,"activeCount":99},[],{"trials":2220,"activeCount":99},[],{"trials":2222,"activeCount":99},[2223],{"nctId":2224,"briefTitle":2225,"status":1658,"phases":2226,"primaryCompletion":2227,"completion":2228,"start":2229,"enrollment":184,"conditions":2230,"interventions":2232},"NCT06112522","Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma",[89],"2024-12-01","2025-12-01","2024-02-16",[2231],"Cell Carcinoma",[2215],{"trials":2234,"activeCount":99},[],{"trials":2236,"activeCount":99},[],{"trials":2238,"activeCount":99},[],{"intervention":2240,"totalTrials":95,"cells":2241},"New trio de Kligman",{"EARLY_PHASE1":2242,"PHASE1":2244,"PHASE2":2246,"PHASE3":2258,"PHASE4":2260,"NA":2262},{"trials":2243,"activeCount":99},[],{"trials":2245,"activeCount":99},[],{"trials":2247,"activeCount":99},[2248],{"nctId":2249,"briefTitle":2250,"status":359,"phases":2251,"primaryCompletion":2252,"completion":2253,"start":2254,"enrollment":718,"conditions":2255,"interventions":2256},"NCT05119413","Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma",[89],"2022-09-16","2022-12-15","2021-11-30",[1389],[2240,2257],"Trio Kligman",{"trials":2259,"activeCount":99},[],{"trials":2261,"activeCount":99},[],{"trials":2263,"activeCount":99},[],{"intervention":2257,"totalTrials":95,"cells":2265},{"EARLY_PHASE1":2266,"PHASE1":2268,"PHASE2":2270,"PHASE3":2276,"PHASE4":2278,"NA":2280},{"trials":2267,"activeCount":99},[],{"trials":2269,"activeCount":99},[],{"trials":2271,"activeCount":99},[2272],{"nctId":2249,"briefTitle":2250,"status":359,"phases":2273,"primaryCompletion":2252,"completion":2253,"start":2254,"enrollment":718,"conditions":2274,"interventions":2275},[89],[1389],[2240,2257],{"trials":2277,"activeCount":99},[],{"trials":2279,"activeCount":99},[],{"trials":2281,"activeCount":99},[],{"intervention":2283,"totalTrials":95,"cells":2284},"Peginterferon Alfa-2A 180 MCG\u002FML Injectable Solution",{"EARLY_PHASE1":2285,"PHASE1":2287,"PHASE2":2289,"PHASE3":2300,"PHASE4":2302,"NA":2304},{"trials":2286,"activeCount":99},[],{"trials":2288,"activeCount":99},[],{"trials":2290,"activeCount":99},[2291],{"nctId":2292,"briefTitle":2293,"status":1658,"phases":2294,"primaryCompletion":2295,"completion":2296,"start":2297,"enrollment":472,"conditions":2298,"interventions":2299},"NCT05941845","Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy",[89],"2025-01-24","2025-07-24","2023-07-24",[380],[2283],{"trials":2301,"activeCount":99},[],{"trials":2303,"activeCount":99},[],{"trials":2305,"activeCount":99},[],{"intervention":2307,"totalTrials":95,"cells":2308},"BEVACIZUMAB",{"EARLY_PHASE1":2309,"PHASE1":2311,"PHASE2":2313,"PHASE3":2325,"PHASE4":2327,"NA":2329},{"trials":2310,"activeCount":99},[],{"trials":2312,"activeCount":99},[],{"trials":2314,"activeCount":99},[2315],{"nctId":2316,"briefTitle":2317,"status":1383,"phases":2318,"primaryCompletion":2319,"completion":2320,"start":2321,"enrollment":718,"conditions":2322,"interventions":2324},"NCT00565656","A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts",[89],"2009-07","2010-07","2007-07",[2323],"Myelodysplastic Syndromes",[2307],{"trials":2326,"activeCount":99},[],{"trials":2328,"activeCount":99},[],{"trials":2330,"activeCount":99},[],{"intervention":2332,"totalTrials":95,"cells":2333},"1% pimecrolimus cream",{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2338,"PHASE3":2349,"PHASE4":2351,"NA":2353},{"trials":2335,"activeCount":99},[],{"trials":2337,"activeCount":99},[],{"trials":2339,"activeCount":99},[2340],{"nctId":2341,"briefTitle":2342,"status":1383,"phases":2343,"completion":2344,"start":1456,"enrollment":2345,"conditions":2346,"interventions":2348},"NCT00321750","Treatment of Oral Erosive Lichen Planus With Pimecrolimus Cream",[89],"2005-04",14,[2347],"Oral Erosive Lichen Planus",[2332],{"trials":2350,"activeCount":99},[],{"trials":2352,"activeCount":99},[],{"trials":2354,"activeCount":99},[],{"intervention":2356,"totalTrials":95,"cells":2357},"Avdoralimab",{"EARLY_PHASE1":2358,"PHASE1":2360,"PHASE2":2362,"PHASE3":2374,"PHASE4":2376,"NA":2378},{"trials":2359,"activeCount":99},[],{"trials":2361,"activeCount":99},[],{"trials":2363,"activeCount":99},[2364],{"nctId":2365,"briefTitle":2366,"status":359,"phases":2367,"primaryCompletion":2368,"completion":2369,"start":2370,"enrollment":878,"conditions":2371,"interventions":2373},"NCT04563923","Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody",[89],"2023-04-30","2024-03-31","2020-10-10",[2372],"Bullous Pemphigoid",[2356],{"trials":2375,"activeCount":99},[],{"trials":2377,"activeCount":99},[],{"trials":2379,"activeCount":99},[],{"intervention":2381,"totalTrials":95,"cells":2382},"Ruxolitinib Topical",{"EARLY_PHASE1":2383,"PHASE1":2385,"PHASE2":2387,"PHASE3":2398,"PHASE4":2400,"NA":2402},{"trials":2384,"activeCount":99},[],{"trials":2386,"activeCount":99},[],{"trials":2388,"activeCount":99},[2389],{"nctId":2390,"briefTitle":2391,"status":359,"phases":2392,"primaryCompletion":2393,"completion":2394,"start":2395,"enrollment":599,"conditions":2396,"interventions":2397},"NCT05872477","Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas",[89],"2024-02-08","2025-01-10","2023-09-05",[21],[2381],{"trials":2399,"activeCount":99},[],{"trials":2401,"activeCount":99},[],{"trials":2403,"activeCount":99},[],{"intervention":2405,"totalTrials":95,"cells":2406},"Metformin Group",{"EARLY_PHASE1":2407,"PHASE1":2409,"PHASE2":2411,"PHASE3":2423,"PHASE4":2425,"NA":2427},{"trials":2408,"activeCount":99},[],{"trials":2410,"activeCount":99},[],{"trials":2412,"activeCount":99},[2413],{"nctId":2414,"briefTitle":2415,"status":359,"phases":2416,"primaryCompletion":2417,"completion":2418,"start":2419,"enrollment":599,"conditions":2420,"interventions":2422},"NCT01840007","Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma",[89],"2015-05-28","2015-11-18","2011-08-30",[2421],"Metastatic Melanoma (Stage IIIC Non-résécable or no Surgically Curable or Stage IV With Classification AJCC)",[2405],{"trials":2424,"activeCount":99},[],{"trials":2426,"activeCount":99},[],{"trials":2428,"activeCount":99},[],{"intervention":2430,"totalTrials":95,"cells":2431},"Atorvastatin",{"EARLY_PHASE1":2432,"PHASE1":2434,"PHASE2":2436,"PHASE3":2448,"PHASE4":2450,"NA":2452},{"trials":2433,"activeCount":99},[],{"trials":2435,"activeCount":99},[],{"trials":2437,"activeCount":99},[2438],{"nctId":2439,"briefTitle":2440,"status":359,"phases":2441,"primaryCompletion":2442,"completion":2443,"start":2444,"enrollment":2445,"conditions":2446,"interventions":2447},"NCT02432534","Atorvastatin in Active Vitiligo",[89],"2017-02","2017-12","2015-05",28,[21],[2430],{"trials":2449,"activeCount":99},[],{"trials":2451,"activeCount":99},[],{"trials":2453,"activeCount":99},[],{"intervention":2455,"totalTrials":95,"cells":2456},"Picato gel",{"EARLY_PHASE1":2457,"PHASE1":2459,"PHASE2":2461,"PHASE3":2472,"PHASE4":2474,"NA":2476},{"trials":2458,"activeCount":99},[],{"trials":2460,"activeCount":99},[],{"trials":2462,"activeCount":99},[2463],{"nctId":2464,"briefTitle":2465,"status":359,"phases":2466,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":599,"conditions":2469,"interventions":2471},"NCT02723721","Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face",[89],"2020-01-27","2016-06-15",[2470],"Lentigo Maligna",[2455],{"trials":2473,"activeCount":99},[],{"trials":2475,"activeCount":99},[],{"trials":2477,"activeCount":99},[],{"intervention":2479,"totalTrials":95,"cells":2480},"Bacilor",{"EARLY_PHASE1":2481,"PHASE1":2483,"PHASE2":2485,"PHASE3":2497,"PHASE4":2499,"NA":2501},{"trials":2482,"activeCount":99},[],{"trials":2484,"activeCount":99},[],{"trials":2486,"activeCount":99},[2487],{"nctId":2488,"briefTitle":2489,"status":359,"phases":2490,"primaryCompletion":2491,"completion":2492,"start":2493,"enrollment":599,"conditions":2494,"interventions":2496},"NCT02789605","Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis",[89],"2019-11-25","2020-07-15","2018-01-04",[2495],"Aphthous Stomatitis",[2479],{"trials":2498,"activeCount":99},[],{"trials":2500,"activeCount":99},[],{"trials":2502,"activeCount":99},[],{"intervention":2504,"totalTrials":95,"cells":2505},"Polyphenon E before Placebo",{"EARLY_PHASE1":2506,"PHASE1":2508,"PHASE2":2510,"PHASE3":2520,"PHASE4":2522,"NA":2524},{"trials":2507,"activeCount":99},[],{"trials":2509,"activeCount":99},[],{"trials":2511,"activeCount":99},[2512],{"nctId":2513,"briefTitle":2514,"status":359,"phases":2515,"primaryCompletion":1411,"completion":1411,"start":1873,"enrollment":2516,"conditions":2517,"interventions":2519},"NCT00951964","Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)",[89],18,[2518],"Epidermolysis Bullosa Dystrophica",[2504],{"trials":2521,"activeCount":99},[],{"trials":2523,"activeCount":99},[],{"trials":2525,"activeCount":99},[],{"intervention":2527,"totalTrials":95,"cells":2528},"Apremilast",{"EARLY_PHASE1":2529,"PHASE1":2531,"PHASE2":2533,"PHASE3":2543,"PHASE4":2545,"NA":2547},{"trials":2530,"activeCount":99},[],{"trials":2532,"activeCount":99},[],{"trials":2534,"activeCount":99},[2535],{"nctId":2536,"briefTitle":2537,"status":359,"phases":2538,"primaryCompletion":2539,"completion":2491,"start":2540,"enrollment":1920,"conditions":2541,"interventions":2542},"NCT03036995","Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO",[89],"2018-11-08","2017-03-20",[21],[2527],{"trials":2544,"activeCount":99},[],{"trials":2546,"activeCount":99},[],{"trials":2548,"activeCount":99},[],{"intervention":2550,"totalTrials":95,"cells":2551},"CTB by nasal way",{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2568,"PHASE3":2570,"PHASE4":2572,"NA":2574},{"trials":2553,"activeCount":99},[],{"trials":2555,"activeCount":99},[2556],{"nctId":2557,"briefTitle":2558,"status":359,"phases":2559,"primaryCompletion":2560,"completion":2561,"start":2560,"enrollment":718,"conditions":2562,"interventions":2564},"NCT00820144","Cholera Toxin B Subunit (CTB) Administered by Mucosal Way in Healthy Adult Volunteer",[88],"2006-04","2007-02",[2563],"Infection",[2550,2565,2566,2567,2567],"absorption of CTB by oral way","absorption of dukoral by oral way","absorption of CTB by sublingual way",{"trials":2569,"activeCount":99},[],{"trials":2571,"activeCount":99},[],{"trials":2573,"activeCount":99},[],{"trials":2575,"activeCount":99},[],{"intervention":2565,"totalTrials":95,"cells":2577},{"EARLY_PHASE1":2578,"PHASE1":2580,"PHASE2":2586,"PHASE3":2588,"PHASE4":2590,"NA":2592},{"trials":2579,"activeCount":99},[],{"trials":2581,"activeCount":99},[2582],{"nctId":2557,"briefTitle":2558,"status":359,"phases":2583,"primaryCompletion":2560,"completion":2561,"start":2560,"enrollment":718,"conditions":2584,"interventions":2585},[88],[2563],[2550,2565,2566,2567,2567],{"trials":2587,"activeCount":99},[],{"trials":2589,"activeCount":99},[],{"trials":2591,"activeCount":99},[],{"trials":2593,"activeCount":99},[],{"intervention":2566,"totalTrials":95,"cells":2595},{"EARLY_PHASE1":2596,"PHASE1":2598,"PHASE2":2604,"PHASE3":2606,"PHASE4":2608,"NA":2610},{"trials":2597,"activeCount":99},[],{"trials":2599,"activeCount":99},[2600],{"nctId":2557,"briefTitle":2558,"status":359,"phases":2601,"primaryCompletion":2560,"completion":2561,"start":2560,"enrollment":718,"conditions":2602,"interventions":2603},[88],[2563],[2550,2565,2566,2567,2567],{"trials":2605,"activeCount":99},[],{"trials":2607,"activeCount":99},[],{"trials":2609,"activeCount":99},[],{"trials":2611,"activeCount":99},[],{"intervention":2567,"totalTrials":95,"cells":2613},{"EARLY_PHASE1":2614,"PHASE1":2616,"PHASE2":2622,"PHASE3":2624,"PHASE4":2626,"NA":2628},{"trials":2615,"activeCount":99},[],{"trials":2617,"activeCount":99},[2618],{"nctId":2557,"briefTitle":2558,"status":359,"phases":2619,"primaryCompletion":2560,"completion":2561,"start":2560,"enrollment":718,"conditions":2620,"interventions":2621},[88],[2563],[2550,2565,2566,2567,2567],{"trials":2623,"activeCount":99},[],{"trials":2625,"activeCount":99},[],{"trials":2627,"activeCount":99},[],{"trials":2629,"activeCount":99},[],{"intervention":2631,"totalTrials":348,"cells":2632},"MEOPA",{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2639,"PHASE4":2641,"NA":2651},{"trials":2634,"activeCount":99},[],{"trials":2636,"activeCount":99},[],{"trials":2638,"activeCount":99},[],{"trials":2640,"activeCount":99},[],{"trials":2642,"activeCount":99},[2643],{"nctId":2644,"briefTitle":2645,"status":1658,"phases":2646,"primaryCompletion":2444,"completion":2647,"start":1729,"enrollment":1661,"conditions":2648,"interventions":2650},"NCT02230007","Contribution of the MEOPA in the Physiotherapy Care of Painful Articular Steepness Among Elderly",[91],"2015-07",[2649],"Pain Management and Care",[2631],{"trials":2652,"activeCount":99},[2653],{"nctId":2654,"briefTitle":2655,"status":359,"phases":2656,"primaryCompletion":1731,"completion":1731,"start":2657,"enrollment":184,"conditions":2658,"interventions":2660},"NCT00822224","Use of MEOPA (Equimolar Mixture of Nitrogen Protoxide and Oxygen) for Elderly With Dementia",[92],"2009-01",[2659],"Dementia",[2631],{"intervention":2662,"totalTrials":348,"cells":2663},"Ropivacaine",{"EARLY_PHASE1":2664,"PHASE1":2666,"PHASE2":2668,"PHASE3":2670,"PHASE4":2672,"NA":2682},{"trials":2665,"activeCount":99},[],{"trials":2667,"activeCount":99},[],{"trials":2669,"activeCount":99},[],{"trials":2671,"activeCount":99},[],{"trials":2673,"activeCount":99},[2674],{"nctId":2675,"briefTitle":2676,"status":1383,"phases":2677,"primaryCompletion":1386,"completion":1896,"start":2678,"enrollment":113,"conditions":2679,"interventions":2681},"NCT00823576","Efficacy of Ropivacaine Continuous Wound Instillation Versus Single Shot After Spine Fusion Surgery",[91],"2008-12",[2680],"Postoperative Pain",[2662],{"trials":2683,"activeCount":99},[2684],{"nctId":2685,"briefTitle":2686,"status":359,"phases":2687,"primaryCompletion":2688,"completion":2689,"start":2690,"enrollment":113,"conditions":2691,"interventions":2693},"NCT04555291","Analgesic Effect of the QLB-3 for Patients Undergoing a Total Hip Surgery",[92],"2023-10-06","2024-10-10","2022-01-05",[2692],"Total Hip Arthroplasty",[2662],{"intervention":2695,"totalTrials":348,"cells":2696},"Glisodin",{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2701,"PHASE3":2703,"PHASE4":2705,"NA":2707},{"trials":2698,"activeCount":99},[],{"trials":2700,"activeCount":99},[],{"trials":2702,"activeCount":99},[],{"trials":2704,"activeCount":99},[],{"trials":2706,"activeCount":99},[],{"trials":2708,"activeCount":99},[2709,2718],{"nctId":2710,"briefTitle":2711,"status":359,"phases":2712,"primaryCompletion":2713,"completion":2714,"start":2715,"enrollment":184,"conditions":2716,"interventions":2717},"NCT03941808","Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo.",[92],"2020-05-02","2020-12-01","2019-06-17",[21],[2695],{"nctId":2719,"briefTitle":2720,"status":359,"phases":2721,"primaryCompletion":2722,"completion":2723,"start":2724,"enrollment":718,"conditions":2725,"interventions":2727},"NCT03878433","Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.",[92],"2020-01-01","2020-07-01","2019-04-01",[2726],"Melasma",[2695],{"intervention":2729,"totalTrials":348,"cells":2730},"Blood test",{"EARLY_PHASE1":2731,"PHASE1":2733,"PHASE2":2735,"PHASE3":2737,"PHASE4":2739,"NA":2741},{"trials":2732,"activeCount":99},[],{"trials":2734,"activeCount":99},[],{"trials":2736,"activeCount":99},[],{"trials":2738,"activeCount":99},[],{"trials":2740,"activeCount":99},[],{"trials":2742,"activeCount":99},[2743,2753],{"nctId":2744,"briefTitle":2745,"status":359,"phases":2746,"primaryCompletion":2747,"completion":2747,"start":2748,"enrollment":2749,"conditions":2750,"interventions":2752},"NCT01970735","Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2",[92],"2014-12-16","2013-10-30",103,[2751],"Muscular Dystrophy, Facioscapulohumeral",[2729],{"nctId":2754,"briefTitle":2755,"status":359,"phases":2756,"primaryCompletion":2757,"completion":2758,"start":2759,"enrollment":878,"conditions":2760,"interventions":2762},"NCT02310451","Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes",[92],"2015-12","2023-07-31","2014-12",[2761],"Metastatic Melanoma",[2763],"blood test",{"intervention":2765,"totalTrials":95,"cells":2766},"telmisartan during 6 months",{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2771,"PHASE3":2773,"PHASE4":2775,"NA":2777},{"trials":2768,"activeCount":99},[],{"trials":2770,"activeCount":99},[],{"trials":2772,"activeCount":99},[],{"trials":2774,"activeCount":99},[],{"trials":2776,"activeCount":99},[],{"trials":2778,"activeCount":99},[2779],{"nctId":2780,"briefTitle":2781,"status":359,"phases":2782,"primaryCompletion":2783,"completion":2784,"start":2785,"enrollment":599,"conditions":2786,"interventions":2788},"NCT02768948","Telmisartan Promotes the Differentiation of Monocytes Into Macrophages M2 in Diabetic Nephropathy?",[92],"2019-09-11","2020-07-11","2017-05-05",[2787],"Diabetic Nephropathy",[2765,2789],"Losartan during 6 months",{"intervention":2789,"totalTrials":95,"cells":2791},{"EARLY_PHASE1":2792,"PHASE1":2794,"PHASE2":2796,"PHASE3":2798,"PHASE4":2800,"NA":2802},{"trials":2793,"activeCount":99},[],{"trials":2795,"activeCount":99},[],{"trials":2797,"activeCount":99},[],{"trials":2799,"activeCount":99},[],{"trials":2801,"activeCount":99},[],{"trials":2803,"activeCount":99},[2804],{"nctId":2780,"briefTitle":2781,"status":359,"phases":2805,"primaryCompletion":2783,"completion":2784,"start":2785,"enrollment":599,"conditions":2806,"interventions":2807},[92],[2787],[2765,2789],{"intervention":2809,"totalTrials":95,"cells":2810},"Analysis on colorectal biopsy",{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2815,"PHASE3":2817,"PHASE4":2819,"NA":2821},{"trials":2812,"activeCount":99},[],{"trials":2814,"activeCount":99},[],{"trials":2816,"activeCount":99},[],{"trials":2818,"activeCount":99},[],{"trials":2820,"activeCount":99},[],{"trials":2822,"activeCount":99},[2823],{"nctId":2824,"briefTitle":2825,"status":1610,"phases":2826,"primaryCompletion":2827,"completion":2827,"start":2828,"enrollment":99,"conditions":2829,"interventions":2831},"NCT02841878","Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome",[92],"2018-09","2016-09",[2830],"Irritable Bowel Syndrome (IBS)",[2809],{"intervention":2833,"totalTrials":95,"cells":2834},"Omega-3 Fatty Acid",{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2839,"PHASE3":2841,"PHASE4":2843,"NA":2845},{"trials":2836,"activeCount":99},[],{"trials":2838,"activeCount":99},[],{"trials":2840,"activeCount":99},[],{"trials":2842,"activeCount":99},[],{"trials":2844,"activeCount":99},[],{"trials":2846,"activeCount":99},[2847],{"nctId":2848,"briefTitle":2849,"status":359,"phases":2850,"primaryCompletion":2851,"completion":2852,"start":2853,"enrollment":1801,"conditions":2854,"interventions":2856},"NCT03006016","Preoperative Omega-3 Polyunsaturated Fatty Acids in Morbidly Obese to Reduce Liver Volume and Steatosis",[92],"2020-03-31","2020-08-07","2017-04-12",[2855],"Morbid Obesity D009765",[2833],{"intervention":2858,"totalTrials":95,"cells":2859},"Modification for administration mode of cloxacillin antibiotic",{"EARLY_PHASE1":2860,"PHASE1":2862,"PHASE2":2864,"PHASE3":2866,"PHASE4":2868,"NA":2870},{"trials":2861,"activeCount":99},[],{"trials":2863,"activeCount":99},[],{"trials":2865,"activeCount":99},[],{"trials":2867,"activeCount":99},[],{"trials":2869,"activeCount":99},[],{"trials":2871,"activeCount":99},[2872],{"nctId":2873,"briefTitle":2874,"status":359,"phases":2875,"primaryCompletion":2876,"completion":2877,"start":2876,"enrollment":19,"conditions":2878,"interventions":2881},"NCT03246360","Pharmacological Comparison of Continuous and Intermittent Infusions of Cloxacillin",[92],"2017-11-23","2018-09-18",[2563,2879,2880],"Methicillin Susceptible Staphylococcus Aureus Infection","Cloxacillin Treatment",[2858],{"intervention":2883,"totalTrials":95,"cells":2884},"periodontal pocket samples",{"EARLY_PHASE1":2885,"PHASE1":2887,"PHASE2":2889,"PHASE3":2891,"PHASE4":2893,"NA":2895},{"trials":2886,"activeCount":99},[],{"trials":2888,"activeCount":99},[],{"trials":2890,"activeCount":99},[],{"trials":2892,"activeCount":99},[],{"trials":2894,"activeCount":99},[],{"trials":2896,"activeCount":99},[2897],{"nctId":2898,"briefTitle":2899,"status":359,"phases":2900,"primaryCompletion":2901,"completion":2902,"start":2903,"enrollment":2904,"conditions":2905,"interventions":2907},"NCT02180932","Towards a Viral Etiology of Periodontal Disease in Relation to Radiotherapy Treatment of Head and Neck Cancers",[92],"2015-07-03","2015-12-03","2014-10-20",25,[2906],"Periodontal Disease",[2883],{"intervention":2909,"totalTrials":95,"cells":2910},"venous lactate",{"EARLY_PHASE1":2911,"PHASE1":2913,"PHASE2":2915,"PHASE3":2917,"PHASE4":2919,"NA":2921},{"trials":2912,"activeCount":99},[],{"trials":2914,"activeCount":99},[],{"trials":2916,"activeCount":99},[],{"trials":2918,"activeCount":99},[],{"trials":2920,"activeCount":99},[],{"trials":2922,"activeCount":99},[2923],{"nctId":2924,"briefTitle":2925,"status":359,"phases":2926,"primaryCompletion":2927,"completion":2927,"start":2928,"enrollment":2929,"conditions":2930,"interventions":2932},"NCT03325452","Evaluating Prognostic Contribution of Lactate on Recovery of Spontaneous Cardiac Activity After Cardiac Arrest",[92],"2020-08-10","2017-12-19",77,[2931],"Cardio-respiratory Arrest, Prolactin",[2909],{"intervention":2934,"totalTrials":95,"cells":2935},"Sample analysis",{"EARLY_PHASE1":2936,"PHASE1":2938,"PHASE2":2940,"PHASE3":2942,"PHASE4":2944,"NA":2946},{"trials":2937,"activeCount":99},[],{"trials":2939,"activeCount":99},[],{"trials":2941,"activeCount":99},[],{"trials":2943,"activeCount":99},[],{"trials":2945,"activeCount":99},[],{"trials":2947,"activeCount":99},[2948],{"nctId":2949,"briefTitle":2950,"status":1383,"phases":2951,"primaryCompletion":2952,"completion":2953,"start":2954,"enrollment":113,"conditions":2955,"interventions":2958},"NCT03869593","Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria",[],"2022-03-22","2023-09-01","2019-06-03",[2956,2957],"Escherichia Coli Infections","Staphylococcus Aureus",[2934],{"intervention":2960,"totalTrials":95,"cells":2961},"Data analysis",{"EARLY_PHASE1":2962,"PHASE1":2964,"PHASE2":2966,"PHASE3":2968,"PHASE4":2970,"NA":2972},{"trials":2963,"activeCount":99},[],{"trials":2965,"activeCount":99},[],{"trials":2967,"activeCount":99},[],{"trials":2969,"activeCount":99},[],{"trials":2971,"activeCount":99},[],{"trials":2973,"activeCount":99},[2974],{"nctId":2975,"briefTitle":2976,"status":1658,"phases":2977,"primaryCompletion":2978,"completion":622,"start":2979,"enrollment":210,"conditions":2980,"interventions":2982},"NCT05056740","Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic",[],"2023-04-01","2020-06-01",[2981],"Central Nervous System Diseases",[2960],{"intervention":2984,"totalTrials":95,"cells":2985},"samples",{"EARLY_PHASE1":2986,"PHASE1":2988,"PHASE2":2990,"PHASE3":2992,"PHASE4":2994,"NA":2996},{"trials":2987,"activeCount":99},[],{"trials":2989,"activeCount":99},[],{"trials":2991,"activeCount":99},[],{"trials":2993,"activeCount":99},[],{"trials":2995,"activeCount":99},[],{"trials":2997,"activeCount":99},[2998],{"nctId":2999,"briefTitle":3000,"status":359,"phases":3001,"primaryCompletion":3002,"completion":3002,"start":3003,"enrollment":574,"conditions":3004,"interventions":3005},"NCT03216252","DNA QUANTIFICATION TECHNIQUE AS A INTERPRETATION TOOL IN MITOCHONDRIAL DISEASES",[92],"2020-09-30","2018-02-02",[1151],[2984],{"intervention":3007,"totalTrials":95,"cells":3008},"Sample",{"EARLY_PHASE1":3009,"PHASE1":3011,"PHASE2":3013,"PHASE3":3015,"PHASE4":3017,"NA":3019},{"trials":3010,"activeCount":99},[],{"trials":3012,"activeCount":99},[],{"trials":3014,"activeCount":99},[],{"trials":3016,"activeCount":99},[],{"trials":3018,"activeCount":99},[],{"trials":3020,"activeCount":99},[3021],{"nctId":3022,"briefTitle":3023,"status":1610,"phases":3024,"primaryCompletion":3025,"completion":3025,"start":3026,"enrollment":99,"conditions":3027,"interventions":3029},"NCT05648188","A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells",[],"2024-10-30","2023-01-01",[3028],"Non Small Cell Lung Cancer",[3007],{"intervention":3031,"totalTrials":95,"cells":3032},"Dalbavancin",{"EARLY_PHASE1":3033,"PHASE1":3035,"PHASE2":3037,"PHASE3":3039,"PHASE4":3041,"NA":3043},{"trials":3034,"activeCount":99},[],{"trials":3036,"activeCount":99},[],{"trials":3038,"activeCount":99},[],{"trials":3040,"activeCount":99},[],{"trials":3042,"activeCount":99},[],{"trials":3044,"activeCount":99},[3045],{"nctId":3046,"briefTitle":3047,"status":1658,"phases":3048,"primaryCompletion":361,"completion":361,"start":39,"enrollment":3049,"conditions":3050,"interventions":3052},"NCT05046860","Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements",[92],43,[3051],"Osteoarticular Infection",[3031],{"intervention":3054,"totalTrials":95,"cells":3055},"buccal cavity sample",{"EARLY_PHASE1":3056,"PHASE1":3058,"PHASE2":3060,"PHASE3":3062,"PHASE4":3064,"NA":3066},{"trials":3057,"activeCount":99},[],{"trials":3059,"activeCount":99},[],{"trials":3061,"activeCount":99},[],{"trials":3063,"activeCount":99},[],{"trials":3065,"activeCount":99},[],{"trials":3067,"activeCount":99},[3068],{"nctId":3069,"briefTitle":3070,"status":359,"phases":3071,"primaryCompletion":3072,"completion":3072,"start":3073,"enrollment":16,"conditions":3074,"interventions":3076},"NCT02276573","Study of Inflammatory Role of Epstein-Barr Virus (EBV) in Atrophic and Erosive Forms of Oral Lichen Planus",[92],"2016-03-10","2015-03-30",[3075],"Lichen Planus, Oral",[3054],{"intervention":3078,"totalTrials":95,"cells":3079},"Positive blood culture",{"EARLY_PHASE1":3080,"PHASE1":3082,"PHASE2":3084,"PHASE3":3086,"PHASE4":3088,"NA":3090},{"trials":3081,"activeCount":99},[],{"trials":3083,"activeCount":99},[],{"trials":3085,"activeCount":99},[],{"trials":3087,"activeCount":99},[],{"trials":3089,"activeCount":99},[],{"trials":3091,"activeCount":99},[3092],{"nctId":3093,"briefTitle":3094,"status":359,"phases":3095,"primaryCompletion":3096,"completion":3096,"start":3097,"enrollment":3098,"conditions":3099,"interventions":3102},"NCT05640349","Evaluation of Bacteremia Epidemiology During the COVID Period in One French University Hospital",[],"2022-09-30","2022-04-15",4200,[3100,3101],"Bacteremia","Catheter-Related Infections",[3078],{"intervention":3104,"totalTrials":95,"cells":3105},"Venetoclax and azacitidine combination",{"EARLY_PHASE1":3106,"PHASE1":3108,"PHASE2":3110,"PHASE3":3112,"PHASE4":3114,"NA":3116},{"trials":3107,"activeCount":99},[],{"trials":3109,"activeCount":99},[],{"trials":3111,"activeCount":99},[],{"trials":3113,"activeCount":99},[],{"trials":3115,"activeCount":99},[],{"trials":3117,"activeCount":99},[3118],{"nctId":3119,"briefTitle":3120,"status":359,"phases":3121,"primaryCompletion":361,"completion":3122,"start":3123,"enrollment":599,"conditions":3124,"interventions":3125},"NCT06030089","Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven",[92],"2025-03-03","2024-02-26",[675],[3104],{"intervention":3127,"totalTrials":95,"cells":3128},"Stabilized kilnman trio",{"EARLY_PHASE1":3129,"PHASE1":3131,"PHASE2":3133,"PHASE3":3135,"PHASE4":3137,"NA":3139},{"trials":3130,"activeCount":99},[],{"trials":3132,"activeCount":99},[],{"trials":3134,"activeCount":99},[],{"trials":3136,"activeCount":99},[],{"trials":3138,"activeCount":99},[],{"trials":3140,"activeCount":99},[3141],{"nctId":3142,"briefTitle":3143,"status":359,"phases":3144,"primaryCompletion":1729,"completion":3145,"start":3146,"enrollment":599,"conditions":3147,"interventions":3148},"NCT01850186","Comparative Study of Dual Yellow Laser Versus Stabilized Kilnman Preparation in the Treatment of Melasma",[92],"2013-09","2012-02",[2726],[3127],{"intervention":3150,"totalTrials":95,"cells":3151},"ISET Methode",{"EARLY_PHASE1":3152,"PHASE1":3154,"PHASE2":3156,"PHASE3":3158,"PHASE4":3160,"NA":3162},{"trials":3153,"activeCount":99},[],{"trials":3155,"activeCount":99},[],{"trials":3157,"activeCount":99},[],{"trials":3159,"activeCount":99},[],{"trials":3161,"activeCount":99},[],{"trials":3163,"activeCount":99},[3164],{"nctId":3165,"briefTitle":3166,"status":1658,"phases":3167,"primaryCompletion":3168,"completion":3168,"start":3169,"enrollment":3170,"conditions":3171,"interventions":3172},"NCT00818558","The Method ISET (Insulation by Size of Epithelial Tumor Cells)",[92],"2012-10","2008-10",520,[3028],[3150],{"intervention":3174,"totalTrials":95,"cells":3175},"Conceptio EA",{"EARLY_PHASE1":3176,"PHASE1":3178,"PHASE2":3180,"PHASE3":3182,"PHASE4":3184,"NA":3186},{"trials":3177,"activeCount":99},[],{"trials":3179,"activeCount":99},[],{"trials":3181,"activeCount":99},[],{"trials":3183,"activeCount":99},[],{"trials":3185,"activeCount":99},[],{"trials":3187,"activeCount":99},[3188],{"nctId":3189,"briefTitle":3190,"status":359,"phases":3191,"primaryCompletion":3192,"completion":3193,"start":3194,"enrollment":904,"conditions":3195,"interventions":3197},"NCT01841034","Impact of an Antioxidant Alimentary Complement on Sperm Data",[],"2014-08-30","2015-06-18","2011-05-30",[3196],"Infertility",[3174],{"intervention":3199,"totalTrials":95,"cells":3200},"blood sample",{"EARLY_PHASE1":3201,"PHASE1":3203,"PHASE2":3205,"PHASE3":3207,"PHASE4":3209,"NA":3211},{"trials":3202,"activeCount":99},[],{"trials":3204,"activeCount":99},[],{"trials":3206,"activeCount":99},[],{"trials":3208,"activeCount":99},[],{"trials":3210,"activeCount":99},[],{"trials":3212,"activeCount":99},[3213],{"nctId":3214,"briefTitle":3215,"status":1658,"phases":3216,"primaryCompletion":2759,"completion":3217,"start":2759,"enrollment":3218,"conditions":3219,"interventions":3221},"NCT02300415","Comparison of Sensitivity Between Presepsine and Lactate for the Diagnosis of Severe Sepsis.",[],"2016-12",400,[3220],"Severe Sepsis and Septic Shock",[3199],{"intervention":3223,"totalTrials":95,"cells":3224},"mitochondrial DNA mutations diagnosis",{"EARLY_PHASE1":3225,"PHASE1":3227,"PHASE2":3229,"PHASE3":3231,"PHASE4":3233,"NA":3235},{"trials":3226,"activeCount":99},[],{"trials":3228,"activeCount":99},[],{"trials":3230,"activeCount":99},[],{"trials":3232,"activeCount":99},[],{"trials":3234,"activeCount":99},[],{"trials":3236,"activeCount":99},[3237],{"nctId":3238,"briefTitle":3239,"status":1658,"phases":3240,"start":2678,"enrollment":599,"conditions":3241,"interventions":3244},"NCT00831948","Identification of Large-Scale Mutations of POLG Gene by QMPSF in Patients With Mitochondrial DNA Instability.",[],[1151,3242,3243],"Diagnosis","DNA Mutations",[3223],{"intervention":3246,"totalTrials":95,"cells":3247},"Bacterial species identification by Whole Genome sequencing",{"EARLY_PHASE1":3248,"PHASE1":3250,"PHASE2":3252,"PHASE3":3254,"PHASE4":3256,"NA":3258},{"trials":3249,"activeCount":99},[],{"trials":3251,"activeCount":99},[],{"trials":3253,"activeCount":99},[],{"trials":3255,"activeCount":99},[],{"trials":3257,"activeCount":99},[],{"trials":3259,"activeCount":99},[3260],{"nctId":3261,"briefTitle":3262,"status":359,"phases":3263,"primaryCompletion":3264,"completion":3265,"start":3266,"enrollment":647,"conditions":3267,"interventions":3268},"NCT07598006","Hypervirulent Amoxicillin-Susceptible Klebsiella Pneumoniae CC66, France, 2016-2023",[],"2023-12-12","2025-12-12","2016-01-01",[1103,1104],[3246],{"intervention":3270,"totalTrials":95,"cells":3271},"Genetic test",{"EARLY_PHASE1":3272,"PHASE1":3274,"PHASE2":3276,"PHASE3":3278,"PHASE4":3280,"NA":3282},{"trials":3273,"activeCount":99},[],{"trials":3275,"activeCount":99},[],{"trials":3277,"activeCount":99},[],{"trials":3279,"activeCount":99},[],{"trials":3281,"activeCount":99},[],{"trials":3283,"activeCount":99},[3284],{"nctId":3285,"briefTitle":3286,"status":359,"phases":3287,"primaryCompletion":3288,"completion":3146,"start":3288,"enrollment":113,"conditions":3289,"interventions":3291},"NCT02862340","Study of the Involvement of 15q11 - q13 Chromosome Region and CYFIP1 Gene in Autism. Attempt a Genotype-phenotype Correlation",[92],"2008-01",[3290],"Autistic Disorder",[3270],{"intervention":3293,"totalTrials":95,"cells":3294},"peripheral venous blood samples",{"EARLY_PHASE1":3295,"PHASE1":3297,"PHASE2":3299,"PHASE3":3301,"PHASE4":3303,"NA":3305},{"trials":3296,"activeCount":99},[],{"trials":3298,"activeCount":99},[],{"trials":3300,"activeCount":99},[],{"trials":3302,"activeCount":99},[],{"trials":3304,"activeCount":99},[],{"trials":3306,"activeCount":99},[3307],{"nctId":3308,"briefTitle":3309,"status":1383,"phases":3310,"primaryCompletion":3311,"completion":3311,"start":3312,"enrollment":19,"conditions":3313,"interventions":3315},"NCT02803515","Hyperthermic Intraperitoneal Chemotherapy (HIPEC) : Predictive Marker and Mechanism",[92],"2017-07-02","2017-01-16",[3314],"Peritoneal Carcinomatosis",[3293],{"intervention":3317,"totalTrials":95,"cells":3318},"Isolation of circulating tumor cells (CTC) from veinous blood",{"EARLY_PHASE1":3319,"PHASE1":3321,"PHASE2":3323,"PHASE3":3325,"PHASE4":3327,"NA":3329},{"trials":3320,"activeCount":99},[],{"trials":3322,"activeCount":99},[],{"trials":3324,"activeCount":99},[],{"trials":3326,"activeCount":99},[],{"trials":3328,"activeCount":99},[],{"trials":3330,"activeCount":99},[3331],{"nctId":3332,"briefTitle":3333,"status":359,"phases":3334,"primaryCompletion":3335,"completion":3335,"start":3336,"enrollment":3337,"conditions":3338,"interventions":3341},"NCT02500693","Circulating Tumor Cells in Lung Cancer Screening",[92],"2020-10-13","2015-10-30",683,[3339,3340],"Lung Neoplasms","Pulmonary Disease, Chronic Obstructive",[3317],{"intervention":3343,"totalTrials":95,"cells":3344},"Sedation",{"EARLY_PHASE1":3345,"PHASE1":3347,"PHASE2":3349,"PHASE3":3351,"PHASE4":3353,"NA":3355},{"trials":3346,"activeCount":99},[],{"trials":3348,"activeCount":99},[],{"trials":3350,"activeCount":99},[],{"trials":3352,"activeCount":99},[],{"trials":3354,"activeCount":99},[],{"trials":3356,"activeCount":99},[3357],{"nctId":3358,"briefTitle":3359,"status":1610,"phases":3360,"primaryCompletion":1236,"completion":1236,"start":3361,"enrollment":99,"conditions":3362,"interventions":3364},"NCT04690530","Cerebral Hemodynamics and Oxygenation in Critically Ill Patients",[],"2026-03-01",[3363],"Septic Shock",[3343],{"intervention":3366,"totalTrials":95,"cells":3367},"Unique blod sample",{"EARLY_PHASE1":3368,"PHASE1":3370,"PHASE2":3372,"PHASE3":3374,"PHASE4":3376,"NA":3378},{"trials":3369,"activeCount":99},[],{"trials":3371,"activeCount":99},[],{"trials":3373,"activeCount":99},[],{"trials":3375,"activeCount":99},[],{"trials":3377,"activeCount":99},[],{"trials":3379,"activeCount":99},[3380],{"nctId":3381,"briefTitle":3382,"status":359,"phases":3383,"primaryCompletion":3384,"completion":3384,"start":3385,"enrollment":3386,"conditions":3387,"interventions":3389},"NCT05783349","Predictive Value of Th1, Th2 and Th17 Cytokines on the Success of Embryo Implantation (ImmuNoFertilité)",[92],"2024-02-23","2023-05-04",255,[3388],"Assisted Reproduction",[3366],{"intervention":3391,"totalTrials":95,"cells":3392},"Colostrum feeding",{"EARLY_PHASE1":3393,"PHASE1":3395,"PHASE2":3397,"PHASE3":3399,"PHASE4":3401,"NA":3403},{"trials":3394,"activeCount":99},[],{"trials":3396,"activeCount":99},[],{"trials":3398,"activeCount":99},[],{"trials":3400,"activeCount":99},[],{"trials":3402,"activeCount":99},[],{"trials":3404,"activeCount":99},[3405],{"nctId":3406,"briefTitle":3407,"status":359,"phases":3408,"primaryCompletion":3409,"completion":3410,"start":3411,"enrollment":3412,"conditions":3413,"interventions":3415},"NCT02650167","Impact of Oropharyngeal Administration of Colostrum in the First 48 Hours of Life Term Premature Newborn ≤ 32 Weeks of Amenorrhea",[92],"2018-05-05","2020-09-24","2016-04-27",140,[3414],"Infant, Premature",[3391,3416],"formula for preterm infants",{"intervention":3416,"totalTrials":95,"cells":3418},{"EARLY_PHASE1":3419,"PHASE1":3421,"PHASE2":3423,"PHASE3":3425,"PHASE4":3427,"NA":3429},{"trials":3420,"activeCount":99},[],{"trials":3422,"activeCount":99},[],{"trials":3424,"activeCount":99},[],{"trials":3426,"activeCount":99},[],{"trials":3428,"activeCount":99},[],{"trials":3430,"activeCount":99},[3431],{"nctId":3406,"briefTitle":3407,"status":359,"phases":3432,"primaryCompletion":3409,"completion":3410,"start":3411,"enrollment":3412,"conditions":3433,"interventions":3434},[92],[3414],[3391,3416],{"intervention":3436,"totalTrials":95,"cells":3437},"biphosphonates",{"EARLY_PHASE1":3438,"PHASE1":3440,"PHASE2":3442,"PHASE3":3444,"PHASE4":3446,"NA":3448},{"trials":3439,"activeCount":99},[],{"trials":3441,"activeCount":99},[],{"trials":3443,"activeCount":99},[],{"trials":3445,"activeCount":99},[],{"trials":3447,"activeCount":99},[],{"trials":3449,"activeCount":99},[3450],{"nctId":3451,"briefTitle":3452,"status":359,"phases":3453,"primaryCompletion":3454,"completion":3454,"start":3455,"enrollment":3456,"conditions":3457,"interventions":3460},"NCT05719818","Dental Care and Initiation of Anti-osteoporotic Therapy",[],"2022-01-04","2019-01-03",338,[3458,3459],"Dental Condition","Osteoporosis",[3436],{"intervention":3462,"totalTrials":95,"cells":3463},"Arm A",{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3468,"PHASE3":3470,"PHASE4":3472,"NA":3474},{"trials":3465,"activeCount":99},[],{"trials":3467,"activeCount":99},[],{"trials":3469,"activeCount":99},[],{"trials":3471,"activeCount":99},[],{"trials":3473,"activeCount":99},[],{"trials":3475,"activeCount":99},[3476],{"nctId":3477,"briefTitle":3478,"status":1383,"phases":3479,"primaryCompletion":3480,"completion":3481,"start":3480,"enrollment":599,"conditions":3482,"interventions":3484},"NCT01143311","Role of microRNA in the Development of Cutaneous Squamous Cell Carcinoma",[92],"2010-06","2011-04",[3483],"Cancer of the Skin",[3462],{"intervention":3486,"totalTrials":95,"cells":3487},"Doxycycline",{"EARLY_PHASE1":3488,"PHASE1":3490,"PHASE2":3492,"PHASE3":3494,"PHASE4":3496,"NA":3498},{"trials":3489,"activeCount":99},[],{"trials":3491,"activeCount":99},[],{"trials":3493,"activeCount":99},[],{"trials":3495,"activeCount":99},[],{"trials":3497,"activeCount":99},[],{"trials":3499,"activeCount":99},[3500],{"nctId":3501,"briefTitle":3502,"status":359,"phases":3503,"primaryCompletion":1684,"completion":3504,"start":3505,"enrollment":599,"conditions":3506,"interventions":3508},"NCT02204254","RosaC-RF : Bipolar Radiofrequency vs Doxycycline in Rosacea",[92],"2021-06-07","2014-03",[3507],"Rosacea",[3486],{"intervention":3510,"totalTrials":95,"cells":3511},"quantification of BRAF and NRAS mutation",{"EARLY_PHASE1":3512,"PHASE1":3514,"PHASE2":3516,"PHASE3":3518,"PHASE4":3520,"NA":3522},{"trials":3513,"activeCount":99},[],{"trials":3515,"activeCount":99},[],{"trials":3517,"activeCount":99},[],{"trials":3519,"activeCount":99},[],{"trials":3521,"activeCount":99},[],{"trials":3523,"activeCount":99},[3524],{"nctId":3525,"briefTitle":3526,"status":359,"phases":3527,"primaryCompletion":3528,"completion":3528,"start":3529,"enrollment":1732,"conditions":3530,"interventions":3533},"NCT03493230","Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )",[92],"2022-11-08","2018-04-24",[3531,3532],"Malignant Melanoma Stage IV","Malignant Melanoma Stage III",[3510],{"intervention":3535,"totalTrials":95,"cells":3536},"BNP dosage",{"EARLY_PHASE1":3537,"PHASE1":3539,"PHASE2":3541,"PHASE3":3543,"PHASE4":3545,"NA":3547},{"trials":3538,"activeCount":99},[],{"trials":3540,"activeCount":99},[],{"trials":3542,"activeCount":99},[],{"trials":3544,"activeCount":99},[],{"trials":3546,"activeCount":99},[],{"trials":3548,"activeCount":99},[3549],{"nctId":3550,"briefTitle":3551,"status":359,"phases":3552,"primaryCompletion":3553,"completion":3554,"start":3555,"enrollment":904,"conditions":3556,"interventions":3558},"NCT02570607","Preoperative BNP as Biomarker of Postoperative Cardiovascular Complications",[],"2016-05","2017-05","2015-11",[3557],"Postoperative Cardiovascular Complications",[3535],{"intervention":3560,"totalTrials":95,"cells":3561},"Administration of Almitrine",{"EARLY_PHASE1":3562,"PHASE1":3564,"PHASE2":3566,"PHASE3":3568,"PHASE4":3570,"NA":3572},{"trials":3563,"activeCount":99},[],{"trials":3565,"activeCount":99},[],{"trials":3567,"activeCount":99},[],{"trials":3569,"activeCount":99},[],{"trials":3571,"activeCount":99},[],{"trials":3573,"activeCount":99},[3574],{"nctId":3575,"briefTitle":3576,"status":359,"phases":3577,"primaryCompletion":3578,"completion":3578,"start":3579,"enrollment":3580,"conditions":3581,"interventions":3584},"NCT05216575","Almitrine in COVID-19 Patients With ARDS Treated by HFNO",[],"2022-01-31","2021-01-01",62,[3582,3583],"ARDS","Hypoxemia",[3560]]